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1. INTRODUCTION 
 
In the past few decades, considerable attention has been focused on the 
development of new drug delivery system (NDDS). Carrier-mediated drug delivery 
has emerged as a powerful methodology for the treatment of various pathologies. The 
therapeutic index of traditional and novel drugs is enhanced via the increase of 
specificity due to targeting of drugs to a particular tissue, cell or intracellular 
compartment, the control over release kinetics, the protection of the active agent or a 
combination of the above. 
Targeted drug delivery is the most important goal of pharmaceutical research 
and development. In principle, drug targeting can be achieved by physical or 
biological that result in high concentrations of the pharmacologically active agent at 
the pathophysiologically relevant site. The advantages to the targeted release system 
is the reduction in the frequency of the dosages taken by the patient, having a more 
uniform effect of the drug, reduction of drug side effects, and reduced fluctuation in 
circulating drug levels. 
The result of the targeting would be a significant reduction in drug toxicity, 
reduction of the drug dose, and increased treatment efficacy. TODDS have been 
developed to optimize regenerative techniques. The system is based on a method that 
delivers a certain amount of a therapeutic agent for a prolonged period of time to a 
targeted diseased area within the body. This helps maintain the required plasma and 
tissue drug levels in the body. Therefore, avoiding any damage to the healthy tissue 
via the drug.  
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1.1. Novel Drug Delivery Systems:                                
                            (Shobha Rani R.H.,2008;  Robinson Joseph R, Lee V.H.L., 2009) 
 For past decades, the acute or chronic disease mostly commonly treated by 
the delivery of drug to patients by using various pharmaceutical formulation such as 
capsules, pills, creams, tablets, suppositories, ointments, liquids, aerosols, and 
injections. But to maintain the drug concentration within the therapeutically effective 
range for treatment, it is necessary to take the dosage forms several times a day, 
resulting in significant fluctuations of drug levels in the body. To minimize this 
fluctuation, novel drug delivery systems have been developed, which include 
niosomes, liposomes, nanoparticles, microspheres, micro-emulsions, impalatable 
pumps and magnetic microcapsules.  
The NDDS should ideally fulfill two prerequisites: firstly, it should deliver the 
drug at a rate directed by the needs of the body, over the period of treatment. 
Secondly, it should channel the active entity to the site of action. Conventional dosage 
forms including prolonged release dosage forms are able to meet none of these. At 
present no available drug delivery systems behave ideally, but sincere attempts have 
been made to achieve the above mentioned prerequisites them through various novel 
approaches in drug delivery. 
Recently, different carrier systems and technologies have been extensively 
studied with the aim of controlling the drug release and improving the efficacy and 
selectivity of formulation. Nowadays, vesicles as a carrier system have become the 
vehicle of choice in drug delivery and lipid vesicles were found to be of value in 
immunology, membrane biology, diagnostic technique and most recently in genetic 
engineering. 
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1.2. Targeted Drug Delivery System:               
                                (Banker S.G and Rhodes C.T, 2008; Vyas SP, Khar R.K., 2002) 
By definition targeted drug delivery is a strategy aiming at the delivery of a 
compound to a particular tissue in the body. Ideally, drug targeting would provide a 
high local concentration of drug at the site of disease and a concentration below levels 
of toxicity in healthy tissues. 
 The idea of targeting to a specific site in the body was first introduced almost 
a century ago by Ehrlich. However only in recent years has the field emerged as an 
important area of research. For the new drugs, and for some conventional drugs (e.g., 
antineoplastic agents) that have narrow therapeutic windows and require localization 
to a particular site in the body, it is essential that they be delivered to their target sites 
intact, in adequate concentration, and in an efficient, safe, convenient, and cost-
effective manner. 
 When the drug is administered by the parenteral route, the problems associated 
with the gastrointestinal tract are avoided. However, deactivation and metabolism of 
the drug and dose-related toxicity is frequently observed. There are many diseases 
such as cancer, rheumatoid arthritis and certain bacterial and fungal parasitic infection 
that are inadequately accessible to drugs. The treatment of these diseases often entails 
high frequent dosing of drugs, which can lead to toxic magnifications, inappropriate 
pharmacodisposition and untoward metabolism. Targeted drug delivery system 
designed for cancer predominantly avoids “normal” tissue and targets cancer cell 
specifically. 
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    Fig. 1.1: Diagrammatic representation of challenges facing targeted therapeutics 
 1.2.1. Classification of drug targeting: 
Targeting with drug- carrier system can be divided into three types, they are: 
 Passive targeting 
 Active targeting (ligand mediated targeting and physical 
targeting) 
 Physical targeting 
Passive targeting relies on the natural distribution pattern of the drug- drug-
carrier system. For example, particle with diameter of 5 µm or smaller are readily 
removed from the blood by macrophages of the RES when administered 
systematically. Mechanical filtration of particulate carriers larger than 5-7 µm by 
capillary blockage can also be exploited to target drugs to the lungs by the venous 
supply and to other organs through the appropriate arterial supply.  
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Active targeting employs a deliberately modified drug- drug-carrier molecule 
capable of recognizing and interacting with a specific cell, tissue, or organ in the 
body. Modification of the carrier system may include change in the molecular size, 
alteration of the surface properties, incorporation of antigen-specific anti-bodies, or 
attachment of cell receptor- specific ligands.  
Physical targeting refers to delivery systems that release a drug only when 
exposed to a specific microenvironment such as a change in ph or temperature, or the 
use of an external magnetic field. 
1.2.2. Requirements of Targeted Drug Delivery Systems: 
 Internalize and intracellularly traffic to site of intended action 
 Avoid “normal” tissue 
 Remain intact until reaching its intended site of action 
 The delivery system should be biologically inert  
 It must be non-immunogenic, physically and chemically stable in 
vivo and in vitro. 
 The carrier must be biodegradable or readily eliminated without 
any problem 
 The delivery system must be reproducible cost-effective and 
simple. 
1.2.3. Systems for targeted drug delivery: 
  (Banker S.G and Rhodes C.T, 2008; Robinson Joseph R, Lee V.H.L., 2009; Khar R.K 
and Vyas S.P., 2008) 
Drug- carrier- delivery system employs biologically inert macromolecules to 
direct drug to its target site in the body. These are divided into two types: particulate 
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and soluble macromolecular. Depending on the carrier system, the drug can be either 
molecularly entrapped within the carrier matrix or covalently linked to the carrier 
molecules. 
 Particulate drug delivery systems:  
The concept of using particles to deliver drug to selected sites in the body 
originated from their use in medicine and in the investigation of the RES (liver, 
spleen, and bone marrow), and lymph nodes, gastrointestinal examination, and so on. 
Particle ranging in sizes from 20 to 300µm have been proposed for drug targeting. 
Because of the small size of the particles, particulate drug-delivery system can be 
introduced directly into the central nervous injection or delivered to a given body 
compartment.  
 
 
 
 
 
             
           
Fig. 1.2:   Highly targeted particulate drug carrier system 
 The various particulate drug-carrier system that has been investigated can be 
grouped as following. 
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   Table 1.1. Various carrier and particulate delivery system 
S. 
No 
Carrier 
System 
Size 
Range Features 
Method Of 
Preparation 
1 Solid lipid 
nanoparticle 
50-
1000nm 
Submicron colloidal carriers 
containing solid 
hydrophobic core having a 
monolayer of  phospholipids 
coating. 
.High-pressure 
homogenization 
.Microemulsion 
formation 
.Precipitation 
.As lipid nanopellets 
2 Nanotubes 
and 
Nanowires 
- self-assembling sheet of 
atoms arranged in the form 
of tubes and thread-like 
structures of nanoscale 
range 
Surface 
functionalization 
4 Liposomes 25nm-
100µm 
microscopic vesicles 
composed of one or more 
concentric lipid bilayers, 
separated by water or 
aqueous buffer 
compartments 
.Mechanical dispersion 
.Solvent dispersion 
.Detergent removal 
5 Niosomes 10 to 1000 
nm 
non-ionic surfactant    
vesicles are bilayered 
structures 
-Hand shaking 
-Reverse phase 
evaporation 
-Ether injection method 
-Trans membrane 
6 Lipidmicrot
ubules/ 
microcylind
ers 
<1µm self organizing system in 
which surfactants crystallize 
into tightly packed bilayers 
that spontaneously form 
cylinders 
Self emulsification 
7 Lipospheres 0.2-
100µm 
water dispersible solidmicro 
particles composed of solid 
hydrophobic fat core 
stabilized by a monolayer of 
phospholipids molecules 
embedded in a microparticle 
surface 
.Melt method 
.Multiple microemulsion 
.Cosolvent method 
-Preincorporation into 
lipophilic carrier 
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Particulate drug-delivery system depends on the size, shape, charge and 
surface hydrophobicity of the particles. After intravenous administration, particle 
larger then 7µm are normally mechanically filtered by the smallest capillaries of the 
lungs (particle of 15 µm have been homogeneously distributed throughout the lungs, 
whereas particle of 137 µm exhibited a more peripheral distribution and particle 
smaller than 7µm in diameter (between 2 and 7 µm) may pass the smallest in the 
capillary network of the liver and spleen. For organs that bear solid tumors, this 
approach may lead to localization in the tumor cells.  
For parenteral administration, drug delivery systems to be safe and 
effective they require the following properties: they should be small in particle size 
(nm range), biocompatible, bio-degradable, devoid of immunogenicity, have high 
drug-loading capacity, exhibit long blood circulation , extravasate into the required 
pathological sites and be able to release the drug contents at the target site for 
therapeutic effect. 
Particulate delivery system like liposomes, micelles and polymeric 
nanoparticles has been extensively studied with a great deal of success and provide 
most of the properties desired in delivery systems for parenteral administration. 
Because of their small size and ability to functionalize their surfaces with various 
polymers or ligands, these particles can be used for target specific delivery. Various 
other constructs or assemblies exist which can serve the same function of targeted 
delivery include drug- polymer conjugates, cyclodextrins, niosomes, solid lipid 
particles, lipoproteins, microemulsions, dendrimers, metal nanoparticles, protein 
cages, polyplexes, and cochle. 
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        Table 1.2: Main applications of parenteral particulate drug delivery system 
 
S.no Drug delivery technology              Main applications 
1  Liposome  Passive tumour targeting 
Vaccine adjuvants 
Passive targeting to lung 
endothelium in gene delivery 
Targeting to regional lymph 
nodes 
Targeting to cell surface 
ligands in various organs/areas 
Sustained release 
depot at point of injection 
2  Niosome  Passive tumour targeting 
Vaccine 
adjuvants 
Sustained release depot at point of injection 
3  Nanoparticle  Passive 
tumour targeting 
Vaccine adjuvants 
4  Microparticle  Sustained release depot at 
point of injection 
Vaccine adjuvants 
5  Cyclodextrin  Lipophilic drug solubilisation for 
Parenteral use 
6  Emulsion  Lipophilic drug 
administration vehicles 
Targeting to cell surface antigens 
7  Prodrug 
i) ADEPT 
ii) Polymer drug 
conjugates 
Active tumour 
targeting 
Polymer drug 
conjugates 
8  Polymeric micelles  Active tumour targeting 
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1.2.4. Different Approaches to Drug Targeting: 
                                                                (Gupta Manish and Sharma Vimukutha, 2011) 
 Ligand identification and tumor targeting: 
The identification of suitable ligands is essential for the development of 
efficient targeting strategies. Besides antibodies (e.g. single-chain Fv fragments) 
natural receptor-binding molecules and synthetic peptides can be used as ligands. 
Such new or improved ligands can be obtained by combinatorial and evolutionary 
approaches, e.g. in combination with phage display technology. Several phage display 
ligand libraries have been developed in our group and applied for the isolation of 
specific ligands. For instance, a fully synthetic antibody library was generated, which 
can be employed for the isolation of human scFv fragments against virtually any 
antigen. 
  
          Fig. 1.3: Schematic representation of ligand identification & targeting 
 
 Bispecific antibodies for effector cell retargeting: 
The immune system is composed of an arsenal of different and potent effector 
cells, e.g. cytotoxic T-lymphocytes or NK cells. Recognition and elimination of 
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malignant cells by these effector cells is, however, often not very efficient. Bispecific 
antibodies are capable to redirect effector cells and to trigger killing of target cells, 
thus improving effector cell cytotoxicity. The recombinant bispecific molecules can 
be easily generated and produced by genetic engineering.  
   
                                     Fig. 1.4: Effector cell retargeting 
 Brain targeted drug delivery system:  
The brain is a delicate organ, and evolution built very efficient ways to protect 
it. The delivery of drugs to central nervous system (CNS) is a challenge in the 
treatment of neurological disorders. Drugs may be administered directly into the CNS 
or administered systematically (e.g., by intravenous injection) for targeted action in 
the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), 
which limits the access of drugs to the brain substance. Advances in understanding of 
the cell biology of the BBB have opened new avenues and possibilities for improved 
drug delivery to the CNS. 
A range of strategies that have been used for manipulating the blood-brain 
barrier for drug delivery to the brain include osmotic and chemical opening of the 
blood-brain barrier as well as the use of transport/carrier systems. Other strategies for 
drug delivery to the brain involve bypassing the BBB. 
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           Fig. 1.5: Carrier system to access the relevant target site within the CNS. 
Various pharmacological agents have been used to open the BBB and direct 
invasive methods can introduce therapeutic agents into the brain substance. It is 
important to consider not only the net delivery of the agent to the CNS, but also the 
ability of the agent to access the relevant target site within the CNS. Various routes of 
administration as well as conjugations of drugs, e.g., with liposomes and 
nanoparticles, are considered. 
 Aptamers for Targeted Drug Delivery: 
Aptamers are a class of therapeutic oligonucleotides that form specific three-
dimensional structures that are dictated by their sequences. They are typically 
generated by an iterative screening process of complex nucleic acid libraries 
employing a process termed Systemic Evolution of Ligands by Exponential 
Enrichment (SELEX).  
Therefore, relatively few aptamers have been generated that bind cell surface 
receptors. With cell-based selection, a specific protein target is not always chosen, but 
selection is performed against a target cell type with the goal of letting the aptamer 
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choose the target. All cell surface proteins cycle intracellularly to some extent, and 
many surface receptors are actively internalized in response to ligand binding.  
     
                        Fig. 1.6:  Aptamers for targeted drug delivery 
 Carrier systems for targeted drug delivery: 
Many chemotherapeutics are characterized by a limited therapeutic efficacy, 
often due to severe side effects at higher doses and rapid elimination from the body 
due to their small size. Encapsulation of small therapeutic molecules into 
nanoparticular carrier systems, such as liposomes or polymers, can improve the 
pharmacokinetic and pharmacodynamic properties and protects the active compound 
from degradation.  
 
 
 
 
 
                             Fig. 1.7: Carrier systems for targeted drug delivery 
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1.3. Vesicular system-Carrier for Drug Delivery:        (Raju Jukanti, et al., 2010) 
 
The vesicular systems are highly ordered assemblies of one or several 
concentric lipid bilayer formed, when certain amphiphillic building blocks are 
confronted with water. Vesicles can be formed from a diverse range of amphiphillic 
building blocks. Biologic origin of these vesicles was first reported in 1965 by 
Bingham, and was given the name Bingham bodies. Drug carrier can be engineered to 
slowly degrade, react to stimuli and be site-specific.  
The ultimate aim is to control degradation of drug and loss, prevention of 
harmful side effects and increase the availability of the drug at the disease site. 
Encapsulation of a drug in vesicular structures can be predicted to prolong the 
existence of the drug in systemic circulation, and perhaps, reduces the toxicity if 
selective uptake can be achieved. Lipid vesicles are one type of many experimental 
models of biomembranes which evolved successfully, as vehicles for controlled 
delivery. For the treatment of intracellular infections, conventional chemotherapy is 
not effective, due to limited permeation of drugs into cells. This can overcome by the 
use of Vesicular drug delivery systems.  
1.3.1. Need for Vesicular drug delivery system: 
 Prolong the existence of the drug in systemic circulation, and perhaps, 
reduces the toxicity if selective uptake can be achieved due to the delivery of 
drug directly to the site of infection. 
 Improves the bioavailability especially in the case of poorly soluble drugs. 
 Both hydrophilic and lipophilic drugs can be incorporated. 
 Delays elimination of rapidly metabolizable drugs and thus function as 
sustained release systems.  
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At present, no available drug delivery system behaves ideally, but sincere 
attempts have been made to achieve them through various novel approaches in drug 
delivery. Recently different carrier systems and technologies have been extensively 
studied with the aim of controlling the drug release and improving the efficacy and 
selectivity of formulation. Now a days vesicle as a carrier system have become the 
vehicle of choice in drug delivery and lipid vesicles were found to be of value in 
immunology, membrane biology and diagnostic technique and most recently in 
genetic engineering. 
 
1.3.1. Different novel approaches by vesicular system:  (Ravi Kumar, et al., 2011)                               
 Vesicular delivery system provides an efficient method for delivery to the site 
of infection, leading to reduce of drug toxicity with no adverse effects. Vesicular drug 
delivery reduces the cost of therapy by improved bioavailability of medication, 
especially in case of poorly soluble drugs. They can incorporate both by hydrophilic 
and liophilic drugs. Different novel approaches used for delivering the drugs by 
vesicular system include liposomes, niosomes. sphinosomes, transferosomes and 
pharmacosomes.  
 Liposomes: 
 
The liposomes have emerged as most practically useful carriers for in-vivo 
drug delivery as majority of reports has concentrated on the use of phospholipid 
vesicles or liposomes as potential drug carrier systems. Liposomes are potential carrier 
for controlled drug release of tumours therapeutic agents and antibody  for gene therapy. 
Liposomes are formed when thin lipid films or lipid cakes are hydrated and stacks of 
liquid crystalline bilayers become fluid and swell.  
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    Fig. 1.8: Model of a unilamellar liposome consisting of one double lipid bilayer. 
 Niosomes: 
Niosomes are a novel drug delivery system, in which the medication is 
encapsulated in a vesicle. The vesicle is composed of a bilayer of non-ionic 
surface active agents and hence the name niosomes. The niosomes are very small, 
and microscopic in size. Their size lies in the nanometric scale. Although 
structurally similar to liposomes, they offer several advantages over them.    
                                 
                          Fig. 1.9: Diagrammatic representation of Niosomes 
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 Sphinosomes: 
The sphingolipid (contains ether or amide linkage instead of ester linkage) are 
been nowadays used for the preparation of stable liposomes known as sphingosomes. 
Sphingosome may be defined as “concentric, bilayered vesicle in which an aqueous 
volume is entirely enclosed by a membranous lipid bilayer mainly composed of 
natural or synthetic sphingolipid. 
Sphingosome are administered in many ways these include parentral route of 
administration such as intravenous, intramuscular, subcutaneous, and intra-arterial. 
Generally it will be administered intravenous or some cases by inhalation. Often it 
will be administered into a large central vein, such as the superior vena cava and 
inferior vena cava to allow highly concentrated solution to be administered into large 
volume and flow vessels. 
 Pharmacosomes: 
Pharmacosomes bearing unique advantages over liposome and niosome 
vesicles, have come up as potential alternative to conventional vesicles.  
Depending upon the chemical structure of the drug–lipid complex they may 
exist as ultrafine vesicular, micellar, or hexagonal aggregates. As the system is 
formed by linking a drug (pharmakon) to a carrier (soma), they are termed as 
pharmacosomes. They are an effective tool to achieve desired therapeutic goals such 
as drug targeting and controlled release.  
 
 Transferosomes: 
Transferosomes was introduced for the effective transdermal delivery of 
number of low and high molecular weight drugs. Transfersomes can penetrate the 
intact stratum corneum spontaneously along two routes in the intracellular lipid that 
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differ in their bilayers properties. It consist of both hydrophilic and hydrophobic 
properties, high deformablity gives better penetration of intact vesicles. These 
vesicular transfersomes are several orders of magnitudes more elastic than the 
standard liposomes and thus well suited for the skin penetration.  
Transfersomes overcome the skin penetration difficulty by squeezing 
themselves along the intracellular sealing lipid of the stratum corneum. 
Transferosome based formulations of local anesthetics- lidocaine and tetracaine 
showed permeation equivalent to subcutaneous injections. Anti cancer drugs like 
methotrexate were tried for transdermal delivery using transferosome technology. 
This provided a new approach for treatment especially of skin cancer. 
1.3.2. Emerging Vesicular Drug Delivery System:         (Ravi Kumar, et al., 2011) 
 Aquasomes: Three layered self assembly compositions with ceramics 
carbon nanocrystalline particulate core coated with glassy cellobiose Specific 
Targeting, molecular shielding. 
 Cryptosmes: Lipid vesicles with a surface coat and of suitable 
polyoxoyethylene derivative of phosphotidyl ethanolamine. Ligand mediated drug 
targeting 
 Discomes: Niosomes solublized with non ionic surfactant solutions 
(polyoxyethylene cetyl ether class) Ligand mediated drug targeting 
 Emulsomes: Nanosize Lipid particles (bioadhesives nanoemulsion) 
consisted of microscopic lipid assembly with a polar core. Parenteral delivery of 
poorly water soluble drugs.  
 Enzymosomes: Liposomal constructs engineered to provide a mini  
 Novel Niosomal Delivery System of Etoposide                                          Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur.                                     Page 19 
bioenvironmental in which enzymes are covalently immobilized or coupled to the 
surface of liposomes. Targeted delivery to tumor cell 
 Ethosomes: Lipid “Soft malleable vesicles” embodying a permeation 
enhancer and composed of phospholipid, ethanol and water. Targeted delivery to 
deep skin layer 
 Genosomes: Artificial macromolecular complexes for functional gene 
transfer .Cationic lipids are most suitable because they posess high biodegradability 
and stability in the blood stream. Cell specific gene transfer. 
 Photosomes: Photolysase encapsulated in liposomes, which release the 
content photo-triggered charges in membrane permeability characteristics. 
Photodynamic Therapy 
 Vesosomes: Nested bilayer compartment in vitro via the interdigested 
bilayer phase formed by adding ethanol to a variety of saturated phospholipids. 
Multiple compartment of the vesosomes gives better protection to the interior 
contents in serum. 
    
           Fig. 1.10: Multi compartment structure of vesosomes 
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 Proteosomes: High molecular weight multi-submit enzyme complexes 
with catalytic activity, which is specifically due to the assembly pattern of enzymes. 
Better catalytic activity turnover than non associated enzymes. 
1.4. Niosomes:            
(Jaydeep D Yadav, et al., 2011; Rajesh Z. Mujoriya, et al., 2011; Shobha Rani 
R.H.,2008) 
  Niosomes represent a promising drug delivery module. They are vesicular 
systems similar to liposomes that can be used as carriers of amphiphilic and lipophilic 
drugs. Hence they represent alternative vesicular systems with respect to liposomes, 
due to the niosome ability to encapsulate different type of drugs within their multi 
environmental structure. Niosomes are thoughts to be better candidate’s drug delivery 
as compared to liposomes due to various factors like cost, stability etc. 
1.4.1. Historical aspect: 
  Niosomes were first reported in the seventies as a feature of the 
cosmetic industry by Vanlerberghe et al, Handjani-vila et al., Van Abbe 
explained that the non – inonic surfactants are preferred because the irritation power 
of surfactants decreases in the following order: cationic > anionic > ampholytic > 
non-ionic.  
At present no available drug delivery system achieves the site specific delivery 
with controlled release kinetics of drug in predictable manner.  
Paul Ehrlich, in 1909, initiated the era of development for targeted delivery 
when he envisaged a drug delivery mechanism that would target directly to diseased 
cell. Since then, number of carriers was utilized to carry drug at the target 
 Novel Niosomal Delivery System of Etoposide                                          Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur.                                     Page 21 
organ/tissue, which include immunoglobulins, serum proteins, synthetic polymers, 
liposomes, microspheres, erythrocytes, niosomes etc.  
Among different carriers liposomes and niosomes are well documented drug 
delivery. Niosomes or non-ionic surfactant vesicles are microscopic lamellar 
structures formed on admixture of non-ionic surfactant of the alkyl or dialkyl 
polyglycerol ether class and cholesterol with subsequent hydration in aqueous media.  
1.4.2. Description: 
Structurally, niosomes are similar to liposomes. Both are made up of bilayer, 
which is made up of non-ionic surfactant in the case of niosomes and phospholipids in 
case of liposomes. Both hydrophilic and hydrophobic drugs can be incorporated into 
niosomes. The niosomes are ampiphillic in nature, which allows entrapment of 
hydrophilic drug in the core cavity and hydrophobic drugs in the non-polar region 
present within the bilayer. The structure of niosomes is given in Fig 1.11. 
     
                                       Fig. 1.11: Structure of niosomes 
1.4.3. Advantages of niosomes: 
 They entrap solute in a manner analogous to liposomes. 
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 They are osmotically active and stable. 
 Handling and storage of surfactants requires no special conditions. 
 The surfactants are biodegradable, biocompatible, and nonimmunogenic 
 They possess an infrastructure consisting of hydrophobic and hydrophilic 
moieties together and as a result can accommodate drug molecules with a 
wide range of solubilities. 
 They exhibit flexibility in their structural characteristics (composition, 
fluidity, and size) and can be designed according to desired application. 
 They improve oral bioavailability of poorly absorbed drugs and enhance 
skin penetration of drugs. 
 They allow their surface for attachment of hydrophilic group and can 
incorporate hydrophilic moieties in bilayer to bring about changes in their 
in vivo behavior. 
 They improve the therapeutic performance of the drug molecules by 
delaying the clearance from the circulation, protecting the drug from 
biological environment, and restricting effects to target cells. 
 Niosomal dispersion in an aqueous phase can be emulsified in a 
nonaqueous phase to regulate the delivery rate of drug and administer 
normal vesicle in external nonaqueous phase. 
1.4.4. Types of niosomes: 
 Bola Surfactant Containing Niosomes:  
   Bola surfactant containing niosomes are the surfactants that are made of 
omega-hexadecyl- bis- (1-aza-18 crown-6) (bola surfactant):  span-80/cholesterol in   
2: 3: 1 molar ratio. 
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 Proniosomes:  
   Proniosomes are the niosomal formulation containing carrier and surfactant, 
which requires to be hydrated before being used. The hydration results in the 
formation of aqueous niosome dispersion. Proniosomes decreases the aggregation, 
leaking and fusion problem associated with niosomal formulation.  
 Aspasomes:  
   Combination of acorbyl palmitate, cholesterol and highly charged lipid 
diacetyl phosphate leads to the formation of vesicles called aspasomes. Aspasomes 
are first hydrated with water/aqueous solution and then sonicated to obtain the 
niosomes. Aspasomes can be used to increase the transdermal permeation of drugs. 
Aspasomes have also been used to decrease disorder caused by reactive oxygen 
species as it has inherent antioxidant property. 
1.4.5. Types of niosomal system: 
                                                                              (Surender Verma, et al., 2010) 
 Small unilamellar vesicles: (SUV, size 0.025-0.05 µm) are commonly 
produced by sonication, and French Press procedures. Ultrasonic electrocapillary 
emulsification or solvent dilution techniques can be used to prepare SUVs.  
 Multilamellar vesicles: (MLV, size >0.05 µm) exhibit increased-trapped 
volume and equilibrium solute distribution, and require hand-shaking method. They 
show variations in lipid compositions.  
 Large unilamellar vesicles: (LUV, size >0.10 µm), the injections of lipids 
solubilised in an organic solvent into an aqueous buffer, can result in spontaneous 
formation of LUV.  
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1.4.6. Factors affecting formation of niosomes:     
                                                                                     (Dubey subodh, et al., 2010) 
 Nature of encapsulated drug: 
The physico-chemical properties of encapsulated drug influence charge and 
rigidity of the niosome bilayer. The drug interacts with surfactant head groups and 
develops the charge that creates mutual repulsion between surfactant bilayers and 
hence increases vesicle size. The hydrophilic lipophilic balance of the drug affects 
degree of entrapment. 
                       Table 1.3: Effect of nature of drug  
 
 
S.n
o 
 
Nature of drug 
 
Leakage 
from vesicle 
 
Entrapment 
 
Stability 
 
1 
 
2 
 
3 
 
4 
 
Hydrophobic 
drug 
Hydrophilic 
drug  
Amphiphilic 
drug 
Macromolecule 
 
 
Decreased 
 
Increased 
 
Decreased 
 
Decreased 
 
High 
 
Low 
 
High 
 
- 
 
Increased 
 
Decreased 
 
- 
 
Increased 
 
 Amount and type of surfactant: 
The mean size of niosomes increases proportionally with increase in the HLB 
of surfactants like Span 85 (HLB 1.8) to Span 20 (HLB 8.6) because the surface free 
energy decreases with an increase in hydrophobicity of surfactant. The bilayers of the 
vesicles are either in the so-called liquid state or in gel state, depending on the 
temperature, the type of lipid or surfactant and the presence of other components such 
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as cholesterol. In the gel state, alkyl chains are present in a well-ordered structure, and 
in the liquid state, the structure of the bilayers is more disordered.  
 Cholesterol content and charge: 
Inclusion of cholesterol in niosomes increases its hydrodynamic diameter and 
entrapment efficiency. An increase in cholesterol content of the bilayers resulted in a 
decrease in the release rate of encapsulated material and therefore an increase of the 
rigidity of the bilayers obtained. Presence of charge tends to increase the interlamellar 
distance between successive bilayers in multilamellar vesicle structure and leads to 
greater overall entrapped volume. In general, the action of cholesterol is two folds; on 
one hand, cholesterol increases the chain order of liquid-state bilayers and on the 
other, cholesterol decreases the chain order of gel state bilayers. At a high cholesterol 
concentration, the gel state is transformed to a liquid-ordered phase.  
 Temperature of hydration:  
Hydration temperature influences the shape and size of the noisome. The 
hydrating temperatures used to make niosomes should usually be above the gel to 
liquid phase transition temperature of the system. 
 Membrane composition: 
The stable niosomes can be prepared with addition of different additives along 
with surfactants and drugs. Niosomes formed have a number of morphologies and 
their permeability and stability properties can be altered by manipulating membrane 
characteristics by different additives.  
1.4.7. Similarities between Liposome and Niosome: 
♦ The liposomes and niosomes are functionally same. 
 Novel Niosomal Delivery System of Etoposide                                          Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur.                                     Page 26 
♦ Both can be used in targeted and sustained drug delivery system. 
♦ Property of both depends upon composition of the bilayer and methods of their 
preparation. 
♦ Both increase bioavailability and decrease the body clearance. 
1.4.8. Liposome versus Niosome: 
  Niosomes are now widely studied as an alternative to liposomes, which exhibit 
certain disadvantages such as –they are expensive, their ingredients like phospholipids 
are chemically unstable because of their predisposition to oxidative degradation, they 
require special storage and handling and purity of natural phospholipids is variable. 
The differences between liposomes and niosomes are described in Table 1.4 
             Table 1.4: Comparison of Niosomes with liposomes 
 
NIOSOMES 
 
LIPOSOMES 
 
 Less expensive 
 But non-ionic surfactants 
are stable toward this 
 No special methods are 
required for such 
formulations comparatively 
 Non-ionic surfactants are 
uncharged 
 
 More expensive  
 Phospholipids are prone to 
oxidative degradation  
 Required special method for 
storage, handling and 
purification of  phospholipids 
 Phospholipids may be neutral 
or charged  
 
1.4.9. Therapeutical potentials: 
 Niosomes in Oncology.  
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 Targeting of bioactive agents: 
a) To reticulo-endothelial system (RES) 
b) To organs other than RES 
 Niosomes in leishmaniasis. 
 Niosomes as carriers for Hemoglobin. 
 Niosomes as diagnostic imaging. 
 Transdermal delivery of drugs by niosomes. 
 Niosomes as immunological adjuvant. 
 Niosomes as oral drug delivery niosomes. 
1.5. Cancer: 
  (Stanley R. Hamiton, et al., 2000; Heinz Lullmam, et al., 2000; Goodman and 
Gillman’s, 2008:  http://www. Cancer.org; http:// www.en. Wikipedia.org) 
 Cancer is a class of diseases characterized by out-of-control cell growth. There 
are over 100 different types of cancer, and each is classified by the type of cell that is 
initially affected. Cancer harms the body when damaged cells divide uncontrollably to 
form lumps or masses of tissue called tumors. 
 Cancer is a complex set of diseases. Each cancer is unique in the way it grows 
and develops, its chances of spreading, the way it affects one`s body and the 
symptoms one may experience. Several factors, including location and how the 
cancerous cells appear under the microscope, determine how cancer is diagnosed. All 
cancers, however, fall into one of four broad categories. 
 
 Novel Niosomal Delivery System of Etoposide                                          Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur.                                     Page 28 
Carcinoma:  
 Carcinoma is a malignant neoplasm of epithelial origin. It is a tumor that 
arises in the tissues that line the body`s organs like the nose, the colon, the penis, 
breasts, prostrate, urinary bladder, and the ureter. About 80% of all cancer cases are 
carcinomas. 
Sarcoma: 
  Sarcomas are tumors that originate in bone, muscle, cartilage, fibrous tissue or 
fat. Ewing sarcoma (Family of tumors) and Kaposi`s sarcoma are the common types 
of sarcomas. Ewing sarcoma occurs during the rapid bone growth that generally 
occurs during puberty. The tumor may arise in the long bones of the extremities, most 
often in the femur (thigh bone) or the pelvis. It may also develop in the skull or the 
flat bones of the trunk. This type of tumor is almost never seen in black children. 
Leukemias: 
  Leukemias are cancers of the blood or blood-forming organs. When leukemia 
develops, the body produces a large number of abnormal blood cells. In most types of 
leukemia, the abnormal cells are white blood cells.  
 The leukemia cells usually look different from normal blood cells, and they do 
not function properly. Leukemia can either be acute or chronic. Leukemia cells are 
abnormal cells that cannot do what normal blood cells do. They cannot help the body 
fight infections. 
Lymphomas: 
   Lymphomas affect the lymphatic system, a network of vessels and nodes that 
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acts as the body`s filter. The lymphatic system distributes nutrients to blood and 
tissue, and prevents bacteria and other foreign "invade.  
1.5.1. Burden caused by Cancer: 
Cancer is a group of diseases with similar characteristics, which can occur in 
all living cells in the body and different cancer types have different natural history. 
The myth that cancer affects people mostly in the developed countries is being broken 
by the fact that, of the 10 million new cancer cases seen each year worldwide, nearly 
5.5 million are in the less developed countries. Cancer is the second most common 
cause of death in the developed world and a similar trend has emerged in the 
developing countries too. 
Cancer prevalence in India is estimated to be around 2.5 million, with over    
8,00,000 new cases and 5,50,000 deaths occurring each year due to this disease. More 
than 70% of the cases report for diagnostic and treatment services in the advanced 
stages of the disease, which has lead to a poor survival and high mortality rate. 
The impact of cancer is far greater than mere numbers. Its diagnosis causes 
immense emotional trauma and its treatment, a major economical burden, especially 
in a developing country like India.  
The initial diagnosis of cancer is perceived by many patients as a grave event, 
with more than one-third of them suffering from anxiety and depression. Cancer is 
equally distressing for the family as well. It could greatly affect both the family’s 
daily functioning and economic situation. The economic shock often includes both the 
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loss of income and the increase of expenses because of the treatment and health care. 
Various types of Cancers: 
 Acute lymphoblastic leukemia (ALL) is a form of leukemia, or cancer of the 
white blood cells characterized by excess lymphoblasts. Malignant, immature white 
blood cells continuously multiply and are overproduced in the bone marrow. ALL 
causes damage and death by crowding out normal cells in the bone marrow, and by 
spreading (infiltrating) to other organs. 
 Acute myeloid leukemia (AML), also known as acute myelogenous 
leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid 
growth of abnormal white blood cells that accumulate in the bone marrow and 
interfere with the production of normal blood cells. AML is the most common acute 
leukemia affecting adults, and its incidence increases with age. 
 A brain tumor, or tumour, is an intracranial solid neoplasm, a tumor (defined 
as an abnormal growth of cells) within the brain or the central spinal canal. Brain 
tumors include all tumors inside the cranium or in the central spinal canal. They are 
created by an abnormal and uncontrolled cell division, usually in the brain itself, but 
also in lymphatic tissue, in blood vessels, in the cranial nerves, in the brain envelopes 
(meninges), skull, pituitary gland, or pineal gland. Within the brain itself, the involved 
cells may be neurons or glial cells (which include astrocytes, oligodendrocytes, and 
ependymal cells). Brain tumors may also spread from cancers primarily located in 
other organs (metastatic tumors). 
 Hodgkin's lymphoma, previously known as Hodgkin's disease, is a type of 
lymphoma, which is a cancer originating from white blood cells called lymphocytes. 
 Novel Niosomal Delivery System of Etoposide                                          Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur.                                     Page 31 
It was named after Thomas Hodgkin, who first described abnormalities in the lymph 
system in 1832. Hodgkin's lymphoma is characterized by the orderly spread of disease 
from one lymph node group to another and by the development of systemic symptoms 
with advanced disease. 
 Kaposi's sarcoma (KS) is a tumor caused by Human herpesvirus 8 (HHV8), 
also known as Kaposi's sarcoma-associated herpesvirus (KSHV). It was originally 
described by Moritz Kaposi (KA-po-she), a Hungarian dermatologist practicing at the 
University of Vienna in 1872. 
 Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the 
most common type of liver cancer. Most cases of HCC are secondary to either a viral 
hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common 
cause of hepatic cirrhosis). 
 Lung cancer is a disease characterized by uncontrolled cell growth in tissues 
of the lung. If left untreated, this growth can spread beyond the lung in a process 
called metastasis into nearby tissue and, eventually, into other parts of the body. Most 
cancers that start in lung, known as primary lung cancers, are carcinomas that derive 
from epithelial cells. The main types of lung cancer are small-cell lung cancer 
(SCLC), also called oat cell cancer, and non-small-cell lung cancer (NSCLC). 
 Thymoma is a tumor originating from the epithelial cells of the thymus. 
Thymoma is an uncommon tumor, best known for its association with the 
neuromuscular disorder myasthenia gravis. 
  Uterine sarcomas: sarcomas of the myometrium, or muscular layer of the 
uterus, are most commonly leiomyosarcomas. 
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Acute lymphoblastic leukemia      A brain tumor        Hodgkin's lymphoma 
      
           Stomach cancer         Hepatocellular carcinoma      Lung cancer 
           
 Uterine sarcomas    Nephroblastoma   Kaposi's sarcoma Testicular cancer  
    
    Thymoma                                      Retinoblastoma (Rb) 
                                                   
                                    Fig. 1.12: Various types of Cancers    
 Novel Niosomal Delivery System of Etoposide                                          Introduction 
Adhiparasakthi College of Pharmacy, Melmaruvathur.                                     Page 33 
 Retinoblastoma (Rb) is a rapidly developing cancer that develops in the cells 
of retina, the light-detecting tissue of the eye. In the developed world, Rb has one of 
the best cure rates of all childhood cancers (95-98%), with more than nine out of 
every ten sufferers surviving into adulthood. 
 Kidney cancer is a type of cancer that starts in the cells in the kidney. The 
two most common types of kidney cancer are renal cell carcinoma (RCC) and 
urothelial cell carcinoma (UCC) of the renal pelvis. These names reflect the type of 
cell from which the cancer developed. 
 Testicular cancer is cancer that develops in the testicles, a part of the male 
reproductive system. 
 Stomach cancer, or gastric cancer, refers to cancer arising from any part of 
the stomach. Stomach cancer causes about 800,000 deaths worldwide per year. 
Stomach cancer is often asymptomatic or causes only nonspecific symptoms in its 
early stages. 
 Wilms' tumor or nephroblastoma is cancer of the kidneys that typically 
occurs in children, rarely in adults. Its common name is an eponym, referring to Dr. 
Max Wilms, the German surgeon (1867–1918) who first described this kind of tumor. 
 Neuroblastoma (NB) is the most common extracranial solid cancer in 
childhood and the most common cancer in infancy. It most frequently originates in 
one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, 
abdomen, or pelvis. It is a neuroendocrine tumor, arising from any neural crest 
element of the sympathetic nervous system or SNS. 
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1.5.2.  Risk Factors: 
According to epidemiological studies, 80-90% of all cancers are due to 
environmental factors of which, lifestyle related factors are the most important and 
preventable. The major risk factors for cancer are tobacco, alcohol consumption, 
infections, dietary habits and behavioral factors. Tobacco consumption, either by way 
of chewing or smoking accounts for 50% of all cancers in men. Dietary practices, 
reproductive and sexual practices account for 20-30% of cancers. Studies have shown 
that appropriate changes in lifestyle will reduce the mortality and morbidity caused to 
cancer. This offers the prospect for initiating primary and secondary prevention 
measures for control and prevention of cancers. 
1.5.3. Types of treatment: 
The most common cancer treatments include surgery, radiation therapy, and 
chemotherapy. These therapies may be used either alone or in combination with other 
therapies. Palliative treatment is treatment given to relieve symptoms of cancer and 
cancer treatment, such as pain. Other cancer treatment options include targeted 
therapy, immunotherapy, hormonal therapy, and stem cell/bone marrow 
transplantation. More information on each of these treatments is given below.  
The first treatment a person is given is called first-line therapy. If that 
treatment stops working, then a person receives second-line therapy (and in some 
situations, third-line therapy may be available). Adjuvant therapy is treatment that is 
given after the first treatment (such as chemotherapy after surgery). Neoadjuvant 
therapy is treatment that is given before the primary treatment (such as radiation 
therapy before surgery). 
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 Surgery: 
 
Surgery is the removal of the tumor and surrounding tissue during an operation. It 
is the primary treatment for many types of cancer, and some cancers can be 
completely removed with surgery alone. The side effects of surgery depend on the 
type of surgery and the overall health of the person before surgery. A common side 
effect is pain, there are many ways to provide relief when pain and other side effects 
occur in most people. Surgery may also be used to confirm a diagnosis (such as with a 
surgical biopsy), find out the extent of the cancer (called staging), and relieve side 
effects (such as removing an obstruction to ease pain). 
 Radiation treatment: 
Radiation therapy is the use of high-energy x-rays or other particles to kill 
cancer cells. The most common type of radiation treatment is called external-beam 
radiation therapy, which is radiation given from a machine outside the body. This has 
been considered as a local treatment, as it only affects one part of the body. The goals 
of radiation therapy include shrinking the tumor before surgery, keeping the tumor 
from returning after surgery, eliminating cancer cells in other parts of the body. 
Side effects from radiation therapy may include fatigue, mild skin reactions, 
upset stomach, and loose bowel movements. Internal radiation therapy may cause 
bleeding, infection, or irritation after the implant is removed. Radiation treatment does 
not make a person radioactive. Most side effects go away soon after treatment is 
finished. 
 Chemotherapy:  
   Chemotherapy is the use of drugs to kill cancer cells, usually by stopping the 
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cancer cells’ ability to grow and divide. Systemic chemotherapy is delivered through 
the bloodstream to reach cancer cells throughout the body. A chemotherapy regimen 
(schedule) usually consists of a specific number of cycles given over a set period of 
time. 
 Targeted therapy: 
 Targeted therapy is a treatment that targets the cancer’s specific genes, 
proteins, or the tissue environment that contributes to cancer growth and survival. 
This type of treatment blocks the growth and spread of cancer cells while limiting 
damage to normal cells, usually leading to fewer side effects than other cancer 
medications. 
 Immunotherapy: 
Immunotherapy (also called biologic therapy) is designed to boost the body's 
natural defenses to fight the cancer. It uses materials made either by the body or in a 
laboratory to bolster, target, or restore immune system function. The side effects of 
immunotherapy generally include flu-like symptoms, such as chills, nausea, and fever. 
Immunotherapy also includes cancer vaccines-an investigational approach to helping 
the immune system fight cancer.  
 Hormonal therapy: 
Several types of cancer, including some breast and prostate cancers, only grow 
and spread in the presence of natural chemicals in the body called hormones. 
Hormonal therapy treats cancer by lowering the amounts of hormones in the body. It 
is usually used to treat cancers of the prostate, breast, thyroid, and reproductive 
system. 
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 Stem cell/bone marrow transplantation: 
 
A stem cell transplant is a medical procedure in which diseased bone marrow 
is replaced by highly specialized cells, called hematopoietic stem cells.  
Hematopoietic stem cells are found both in the bloodstream and in the bone 
marrow. Today, this procedure is more commonly called a stem cell transplant, rather 
than bone marrow transplant, because it is the blood stem cells that are typically being  
transplanted, not the actual bone marrow tissue. 
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SURVEY 
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2. LITERATURE SURVEY 
2.1. Literature Review 
1) Farhan J. Ahmad, et al. (2011) had scrutinized the effect of permeation of 
drug into skin by taking three different vesicle size niosomal formulations. The 
combined influence of 3 independent variables in the preparation of venlafaxine 
niosomes by the Ether Injection Method. Seventeen batches were evaluated for 
vesicle size and polydispersity index. Contour plots were constructed to show the 
effects of X1, X2 and X3 on the vesicle size and polydispersity index. Niosomes 
dispersion were found to be stable and preparation of niosomes using factorial design 
was found to be well suited and sound approach to be stable niosomal formulations.  
 
2) Anupriya K., et al. (2011) reported acyclovir niosomes as a possible 
approach to deliver the drug to ophthalmic cavity. Niosomes were formed using 
sorbitan esters (Span 20, 40, 60, and 80) and cholesterol in different molar ratio using 
Reverse phase evaporation method. The formulated niosomes were characterized for 
their in-vitro drug release efficiency, the results indicated that more sustained release 
pattern can be obtained by incorporating the drug in niosomes formed with Span60 
 
3) Jigar Vyas, et al. (2011) entrapped Benzoyl peroxide into niosomes by 
thin film hydration technique to enhance skin penetration as well as to improve skin 
retention of drug, and optimized the various process parameters by partial factorial 
design. The optimized niosomal formulation was incorporated into HPMC K15 gel 
and extensively characterized for percentage drug entrapment (PDE) and in vitro 
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release performance. The stability of the formulation was studied at different 
temperatures. The study demonstrated prolongation of drug release, increased drug 
retention into skin, and improved permeation across the skin after encapsulation of 
benzoyl peroxide into niosomal topical gel. 
4) Chawda H. Singh, et al.  (2011) had designed noisome of Nimesulide and 
evaluated the vesicle size, encapsulation efficiency, in vitro release and physical 
stability of the system. The niosomes prepared by lipid film hydration method were 
multilamellar vesicles and niosomes prepared by ether injection technique were 
unilamellar vesicles. The physical stability study revealed that niosomal preparation 
stored at refrigerated temperature for 60 days had retained maximum drug for all the 
formulation compared to room temperature and elevated temperature conditions. The 
investigations conclusively demonstrated prolongation of drug release at a constant 
and controlled rate after niosomal encapsulation of nimesulide. 
5) Vyas Jigar, et al.  (2011) had formulated erythromycin niosomes by thin 
film hydration technique and various process parameters were optimized by partial 
factorial design. The optimized niosomal formulation was incorporated into carbopol 
gel and extensively characterized for Percentage Drug Entrapment (PDE) and in‐vitro 
release performance. The formulations were subjected to stability study at different 
temperatures.  
6) Lakshmi P K., et al.  (2011) had prepared topical niosomal Urea gel using 
chitosan polymer by both lipid layer hydration and transmembrane pH gradient 
method. Niosomes were characterised for various physical characters. The irritancy 
test was performed by human repeated insult patch test (HRIPT). PASI scoring was 
used to determine the severity of the lesion. Niosomes prepared using span 60 showed 
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a better entrapment than other spans. Both the niosomes showed uniform particle size 
distribution. SEM analysis showed smooth outer surface. A short-term stability 
studies showed that niosomal gel had better stability followed by niosomes prepared 
using transmembrane method and lipid layer hydration method.  
 
7) Vedha Hari B.N., et al. (2011) acquired Orlistat niosomes from 
proniosome to improve its poor and variable oral bioavailability. The non-ionic 
surfactant vesicles are prepared by the reverse phase evaporation technique (slurry 
method). FT-IR data revealed that, compatible and there were no interactions between 
the drug and excipients added in the formulation. SEM images of niosomes with 
various magnifications revealed the mean size of the niosomes were 100 nm with 
smooth surface. Niosome formulation had showed appropriate stability for 90 days by 
storing the formulation at room temperature. They concluded that niosomal 
formulations could be a promising delivery system for Orlistat with improved oral 
bioavailability, stability and for sustained drug release. 
8) Sambhakar S., et al. (2011) had prepared niosomes containing 
Cefuroxime axetil by film formation method. It is characterised by SEM for particle 
size and morphology. The vesicle size and polydispersity index was very low. The in-
vitro release study indicated the controlled release profile of niosomes. In-vitro 
absorption study by everted-sac method showed that maximum absorption was found. 
Stability study indicated that on incorporation of bile salt upto 7.5 mM in the vesicle 
as integral component, the stability was maximum on exposure to 20 mM bile salt, 
whereas they omitted incorporation of bile salt in vesicles, it showed least stability. 
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9) Magharla D., et al. (2010) had fabricated poly (ε-caprolactone) 
microspheres of etoposide by oil in water solvent evaporation technique. The results 
of optimized formulations showed a narrow size distribution and smooth surface. 
They observed microspheres prepared with of 1:10 d/p ratio and 0.5% of PVA have a 
high encapsulation of drug, 65.1% and the in vitro release profile showed a sustained 
etoposide release up to 87.66% at the end of 6 weeks. The DSC and the FTIR analysis 
showed the absence of any potent incompatibility between the drug and the polymer.  
 
10) Kandasamy Ruckmani and veintramuthu sankar. (2010) had 
formulated zidovudine niosomes and optimized by altering the proportion of tween, 
span and cholesterol. The developed niosomes were evaluated for the effect of 
process related variables like hydration time, sonication time, charge inducing agent, 
centrifugation and rotational speed of evoparation flask on zidovudine entrapment 
and release from niosomes. Zidovudine niosome formulated with tween 80 entrapped 
high amount of drug and the addition of DCP enhanced drug release for a longer time 
(88.72% over 12h). 
11) Meenakshi B., et al. (2010) had prepared different batches of metoprolol 
tartrate niosomes by changing the surfactant concentration but keeping the cholesterol 
concentration constant. The prepared niosomes were characterized for particle size, 
entrapment efficiency and drug release studies. They observed that Span 60 based 
formulations have higher entrapment efficiency than other formulations. Also Span 
80 based formulations produced vesicles of smallest size and maximum cumulative 
percent drug release. 
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12) Pavalarani N., et al. (2010) had formulated niosomes of rifampicin and 
gatifloxacin were prepared by lipid hydration technique using rotary flash evaporator. 
The formulated rifampicin and gatifloxacin niosomes showed a vesicle size in the 
range of 100-300nm, the entrapment efficiency were 73% and 70% respectively. The 
invitro release study showed that 98.98% and 97.74% of release of rifampicin and 
gatifloxacin niosomes. 
13) Yan-Zhuo Zhang, et al.  (2010) had prepared stealthy etoposide 
proliposomes and studied the pharmacokinetics in rabbits. Blank stealthy liposome 
was prepared by film dispersion method and stealthy etoposide liposomes were 
prepared by using the ammonium sulfate gradient loading procedure. Encapsulation 
efficiency of stealthy etoposide proliposomes was determined by Sephadex 
chromatography. The pharmacokinetics in rabbits was evaluated by comparison with 
etoposide injection and conventional liposomes. The liposomes were round or oval. 
Intravenous injection was administered at a dose of 1.5 mg/kg Etoposide, the three 
kinds of etoposide preparations were fitted with the two-compartment model. Results 
indicated that the stealthy etoposide proliposomes could significantly extend the 
duration of Etoposide in blood circulation. 
14) Abdul Hasan Sathali A., et al. (2010) had developed a targeted delivery to 
the fungal affected cells. Niosomes of terbinafine hydrochloride were formulated by 
thin film hydration method using different ratios of non ionic surfactant (tween 20, 
40, 60, and 80) and cholesterol with constant drug concentration. The prepared 
formulations were evaluated for its vesicle size (by AFM), entrapment efficiency (by 
dialysis method) in vitro release studies and antifungal activities. Increase in 
surfactant concentration, increased the entrapment efficiency (up to 84.92%) and the 
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formulation with surfactant cholesterol ratio 2:1 in each group of surfactant showed 
good entrapment.  
15) Pandey Shivanand, et al. (2010) had developed Cefpodoxime proxetil 
niosomes by using incorporation of synthetic non-ionic surfactant with cholesterol. 
The encapsulated niosomes were characterized in terms of vesicle shape using a 
scanning electron microscope, particle size determination by optical microscopy, 
compatability studies by Fourier transform infrared spectroscopy, in-vitro drug 
release studies, kinetics of drug release and stability studies of prepared niosomes. 
 
16) Gyanendra singh, et al. (2010) had prepared rifampicin niosome by 
reverse phase evopration method and changed by charge imducing agent (dicetyl 
phosphate).niosome were characterized by determining particle size, polydispersity 
index (PI), zeta potential and scanning electron microscopy. The result of study 
indicates that the investigated system has potential to remain in the desired site for 
prolonged period and is capable of maintaining a constant drug concentration for a 
longer duration. 
17) Lakshmi P K., et al. (2009) had formulated niosomes of salbutamol 
sulphate  using Span 60 as the surfactant, by employing different techniques namely, 
thin film hydration, hand shaking, ether injection, lipid layer hydration and 
transmembrane pH gradient method. The drug encapsulation efficiency varied from 
62 % to 87 %. Transmembrane pH gradient method was found to be most satisfactory 
which released 78.4 % of drug in 24 h. The lyophilized formulation was characterized 
by infrared spectroscopy and conducted tissue distribution studies in albino rats and 
bio- availability studies in rabbits. 
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18) Pratap S J., et al. (2009) had developed nonionic surfactant vesicles 
(niosomes) to improve poor and variable oral bioavailability of Griseofulvin  by thin 
film method and ether injection method using different nonionic surfactants span 20, 
span 40, and span 60. Result indicated that the niosomes prepared by thin film 
method with span 60 provided higher entrapment efficiency. The niosomal 
formulation exhibited significantly retarded in- vitro release and in- vivo study 
revealed that the niosomal dispersion significantly improved the oral bioavailability 
of griseofulvin in albino rats after a single oral dose. Plasma drug profile also 
suggested that the developed niosomal system also has the potential of maintaining 
therapeutic level of griseofulvin for a longer period of time as compared to free 
griseofulvin. 
 
19) Ghada Abdelbary, et al.  (2008) had investigated the feasibility of using 
non-ionic surfactant vesicles (niosomes) as carriers for the ophthalmic controlled 
delivery of a water soluble local antibiotic; Gentamicin sulphate. The ability of these 
vesicles to entrap the studied drug was evaluated by determining the entrapment 
efficiency %EE after centrifugation and separation of the formed vesicles. In-vitro 
drug release results confirmed that niosomal formulations have exhibited a high 
retention of gentamicin sulphate inside the vesicles such that there in vitro release 
was slower compared to the drug solution. Ocular irritancy test performed on albino 
rabbits, showed no sign of irritation for all tested niosomal formulations. 
20) Doijad R.C., et al. (2008) had formulated niosome of cisplatin by ether 
injection method using spans and tweens. They observed highest cumulative percent 
drug release with span-60 (96.87%) and with tween -20 (70.49%) in 12 hours. The in 
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–vivo result that the drug is preferentially targeting to liver followed by spleen and 
lungs. 
21) Varaporn Buraphacheep Junyaprasert, et al.  (2008) had examined an 
influence of different types of membrane additives including negative charge 
(dicetylphosphate, DCP), positive charge (stearylamine, STR) and non-ionic 
molecule (cholesteryl poly-24-oxyethylene ether, SC24) on the physicochemical 
properties of drug-free and drug-loaded niosomes. The results showed that 
incorporation of salicylic acid to the niosomes did not affect zeta potential values, but 
addition of the membrane additives changed the zeta potential depending on the type 
of the additives. Transmission electron microscopy revealed that acid after 3 months 
of storage indicating the good stability. 
 
22) Manivannan Rangasamy, et al.  (2008) had formulated acyclovir 
entrapped niosomes by hand shaking and ether injection process with different ratios 
of (1:1, 1:2 and 1:3) cholesterol (CHOL) and Span-80 (Non-ionic surfactant).The 
niosomes prepared were in the size range of 0.5- 5 microns in the case of hand 
shaking process and 0.5-2.5 microns in the case of Ether injection process. The order 
of encapsulation efficiency increases when span-80 concentration was increased. In-
vitro release study on acyclovir niosomes indicates 76.64% release for formulation 
prepared with CHOL: Span-80 (1:1) and it takes an extended period of 1 day and 16 h 
for release. 
 
23) Roopa Karki, et al. (2008) had encapsulated Isoniazid as niosomal 
formulation using ethanol injection method. A different ratio of cholesterol was used. 
The formulated systems were characterized for in-vitro by size distribution analysis, 
Novel Niosomal Delivery System of Etoposide                                  Literature survey 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 46 
drug entrapment efficiency, drug release profiles and in-vivo drug disposition was 
evaluated in normal, healthy albino rats. In vitro release pattern indicated that about 
total drug content were released within 48 h. The drug disposition by niosomal drug 
delivery proved that the drug accumulated in visceral organs like lung, kidney, liver 
and spleen. This proved that niosomal drug delivery system has lesser toxicity than 
free drug. 
24) Sanaa A. EL-Gizawy, et al. (2007) had designed acyclovir niosomes to 
improve its poor and variable oral bioavailability by the conventional thin film 
hydration method. The percentage entrapment was ~11% and most of the niosomes 
had unilamellar spherical shape. The niosomal formulation exhibited significantly 
retarded release compared with free drug. The in-vivo study revealed that the 
niosomal dispersion significantly improved the oral bioavailability of acyclovir in 
rabbits after a single oral dose of 40 mg kg−1. 
25) Balasubramanian A., et al. (2002) had developed niosome carrying anti 
neoplastic agent Daunorubucin hydrochloride, used in the treatment of acute 
myelocytic leukemia and acute lymphocytic leukemia. The release of the drug from 
the vesicle in – vitro was highly prolonged when compared to the free drug and 
around 22 ½ has more when compared to the free drug. 
26) David G. Rhodes and Almira I. (2001) urbanized proniosomes with a 
maltodextrin carrier, which provides for rapid reconstitution of niosomes with 
minimal residual carrier. SEM images of proniosomes with various degrees of 
surfactant loading and images of pure surfactant were compared. Direct observation 
and particle size measurements by laser light scattering provided characterization of 
the final niosome preparations. The appearance of a coarse, broken surface on the 
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proniosomes correlates with inefficient rehydration and occurrence of aggregation 
and precipitate in the final niosome suspension. These observations provided an 
indication of the requirements for dry proniosomes to yield niosome suspensions of 
high quality. 
27) Gayathri Devi S., et al.  (2000) had formulated niosome of sumatripan 
succanite using lipid hydration method. The prepared noisome were evaluated for 
entrapment efficiency, size analysis in vitro release studies and nasal absorption using 
an ex vivo animal succinate over a period of 6 hour and 98.1% of the drug absorbed 
from the nasal mucosa ex vivo. 
28) Popli H and Nari M.S. (1996) had described the encapsulation of 
tenoxicam in niosome and invetigated the influence of the varying proportion of 
surfactant, cholesterol and dicetyl phosphate on the morphology, particle size 
distribution, entrapment efficiency and in – vitro drug release of noisome. 
 
29) Azmin M. N., et al. (1986) had formulated methotrexate niosomes and 
studied the effect of niosome encapsulation on the metabolism and urinary and faecal 
excretion of methotrexate (MTX) in mice following oral and intravenous 
administration, and compared with the effects of co-administration of free drug and 
polysorbate 80, which does not form vesicles. The entrapped noisome observed to 
reduce the excretion of MTX into urine and bile whereas free polysorbate 80 
increased its excretion. They monitored of the levels of MTX and its 7-hydroxy 
metabolite which indicated that entrapped MTX is protected from rapid metabolism. 
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2.2. DRUG PROFILE 
 
   (IP, 2007; USP, 2007; Goodman and Gillman’s, 2008; Sweetman S.C., Martindale, 
2009; http:// www.google.com, drug bank; http://www.cancer.org) 
 
ETOPOSIDE: 
Etoposide is a semi-synthetic derivative of podophyllotoxin. 
1. Synonyms   : (-)-Etoposide, Etoposidum [INN-Latin], trans- 
         Etoposide. 
 
2. Molecular formula : C29H32O13 
 
 
3. Molecular weight : 588.7 
 
4. IUPAC Name : (10R,11R,15R,16S)-16- {[(2R,4aR,6R,7R,8R,8aS)-  
7,8dihydroxy2methyl-hexahydro-2H-pyrano[3,2-d][1,3] 
dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-
4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}] 
hexadeca-1(9),2,7-trien-12-one. 
 
 
5. Chemical name  : 4′-demethylepipodophyllotoxin-9-[4,6-Oethylidene- β-
D-glucopyranoside] 
 
6. CAS number  : 33419-42-0 
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7.  Category   : Anti-cancer drug. 
 
8. Melting point  : 236-251°C 
 
9. Structural formula: 
 
 
 
 
10. Solubility: 
 
• Slightly soluble in water, slightly soluble in alcohol and chloroform, 
• In ethyl acetate, in methylene chloride, sparingly soluble in methanol. 
 
11. Description:  
 
• White to yellow-brown crystalline powder; 
• White to off-white crystalline. 
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12. Pharmacokinetic data: 
 
 Bioavailability :  Highly variable, 25 to 75% 
 Protein binding :  97% 
 Metabolism  :  Hepatic (CYP3A4 involved) 
 Half-life  :  Oral: 6 h., IV: 6-12 h., IV in children: 3 h. 
 Excretion  :  Renal and fecal 
 Pka   :  9.8 
 logP   :  1.16 
 Nature  :  Hydrophobic 
 
13. Dosage and Administration: 
      Table 2.1: Table indicating dosing Forms & Strengths 
 
 
S.NO 
 
DOSAGE FORMS 
 
STRENGTHS 
1 Capsules 50mg 
2 Injectable solution 20mg/mL 
3 Powder for injection 100mg 
 
 Adult Dosing & Uses: 
 Testicular Cancer: 
 50-100 mg/sq.meter/d IV on days 1-5, OR 
 100 mg/sq.meter/d IV on days 1, 3, 5.Repeat 3-4week. 
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 Small-Cell Lung Cancer (SCLC): 
 35 mg/sq.meter/d IV x 4 d, OR 
 50 mg/sq.meter/d IV x 5 d; repeat q3-4week. 
 Epithelial ovarian cancer: 
 50 mg/m2 daily on days 1 through 21. 
 Germ cell ovarian cancer: 
 100 mg/m2 IV on days 1 through 5. 
 Hodgkin's Disease: 
 100mg/m2/day on days 1, 2 and 3.  
 Total Dose/Cycle = 300 mg/m2. 
14. Mechanism of action: 
 
  Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. 
This causes critical errors in DNA synthesis at the premitotic stage of cell division 
and can lead to apoptosis of the cancer cell. Etoposide is cell cycle dependent and 
phase specific, affecting mainly the S and G2 phases of cell division. 
 
15. Pathway: 
 
Etoposide is a podophyllotoxin derivative that is used in the treatment of 
certain cancers. It inhibits mitosis and induces cell death by acting as a topoisomerase 
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II poison. Topoisomerase II is an enzyme in the nucleus of cells that unwinds DNA by 
making transient double-stranded breaks, relieving the torsion of supercoiled DNA. In 
the unwound form, DNA can serve as a template for DNA replication as well as 
transcription. In the normal state, this effect is transient and the breaks DNA are 
quickly religated by topoisomerase II itself. Etoposide, however, inhibits religation 
and stabilizes the DNA-topoisomerase II complex in the cleaved DNA form, 
ultimately leading to breaks in both DNA chains and cell death. 
Etoposide is also converted into catechol and o-quinone derivatives in the liver and in 
lysosomes respectively. These metabolites are highly oxidative and can directly 
damage DNA, which may also contribute to the drug’s cytotoxic effects. 
 
 
                    Fig. 2.1: Schematic representation of Etoposide pathway 
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16. Therapeutic uses: 
 Autoimmune deficiency syndrome (AIDS)—associated Kaposi's sarcoma 
(a type of cancer of the skin and mucous membranes that is more common 
in patients with AIDS). 
 Cancer in the bone. 
 Cancer of the adrenal cortex (the outside layer of the adrenal gland). 
 Cancer of the endometrium. 
 Cancer of the lung (a certain type of lung cancer usually associated with 
prior smoking, passive smoking, or radon exposure). 
 Cancer of the lymph system (a part of the body's immune system) that 
affects the skin. 
 Cancer of the ovaries (a type of cancer found in the egg-making cells). 
 Cancer of the stomach. 
 Cancer of unknown primary site. 
 Cancers of the blood and lymph system. 
 Cancers of the soft tissues of the body, including the muscles, connective 
tissues (tendons), vessels that carry blood or lymph, or fat. 
 Ewing's sarcoma (a type of cancer found in the bone). 
 Gestational trophoblastic tumors (tumors in the uterus or womb). 
 Hepatoblastoma (a certain type of liver cancer that occurs in children). 
 Multiple myeloma (a certain type of cancer of the blood). 
 Myelodysplastic syndromes (MDS). 
 Neuroblastoma (a cancer of the nerves that usually occurs in children). 
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 Retinoblastoma (a cancer of the eye that usually occurs in children). 
 Thymoma (a cancer of the thymus, which is a small organ that lies under 
the breastbone). 
 Tumors in the brain. 
 Wilms' tumor (a cancer of the kidney that usually occurs in children). 
 Testicular cancer. 
 
17. Toxicities: 
 
 Haematological Toxicity :  
The principal toxicity of etoposide is dose-related bone marrow 
suppression, Leucopenia was observed in 60 to 91 percent and 7 to 17 
percent, of patients, Thrombocytopenia. 
 
 Gastrointestinal Toxicity:  
Nausea and vomiting are the major gastrointestinal toxicities. 
 
 Other Toxicities: 
 
The following reactions have been rarely reported: 
 
 Central nervous system toxicity (somnolence and fatigue) 
 Liver toxicity (transient jaundice and elevated alkaline 
phosphatase), 
 Renal toxicity (elevated urea; hyperuricaemia), 
 Septicaemia during high dose regimens 
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18. Side effects: 
                                      Table 2.2: Side effects of Etoposide 
 
                            
COMMON 
                                  
LESS 
COMMON 
                                        
RARE 
 
♦ Low white blood 
cell count with 
increased risk of 
infection 
♦ Low    blood 
platelet  count 
with   increased 
risk of bleeding 
♦ Nausea    and 
vomiting 
♦ Loss of appetite 
♦ Hair    loss, 
including face 
and body hair 
 
 
♦ Constipation 
♦ Diarrhoea 
♦ Fever and 
chills 
♦ Lowered red 
blood cell 
count 
(anemia) 
 
 
♦ Low blood pressure while drug is 
being given 
♦ Sores in mouth and throat 
♦ Changes in how foods taste 
♦ Rash, which can become serious 
♦ Itching 
♦ Numbness and tingling in hands 
and/or feet 
♦ Allergic reactions (may include 
chills, fever, rapid heart rate, 
trouble breathing, dizziness) 
♦ Increased risk of a second cáncer. 
 
 
19. Drug interactions: 
  Cyclosporine may increase blood levels of etoposide if taken at the same time. 
Any drug that can increase your risk of bleeding may pose a hazard while your blood 
counts are low. Aspirin, ibuprofen, naproxen, and other pain relievers and fever 
reducers can have this effect. Blood thinners such as warfarin may also interact. 
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20. Precautions: 
In all instances where the use of Etoposide is considered for chemotherapy, 
the physician must evaluate the need and usefulness of the drug against the risk of 
adverse reactions. Most such adverse reactions are reversible if detected early. If 
severe reactions occur, the drug should be reduced in dosage or discontinued and 
appropriate corrective measures should be taken. Reinstitution of Etoposide therapy 
should be carried out with caution and with adequate consideration of the further need 
for the drug and alertness as to possible recurrence of toxicity.  
Laboratory Tests: Periodic complete blood counts should be done during the 
course of Etoposide treatment. They should be performed prior to each cycle of 
therapy and at appropriate intervals during andafter therapy. At least one 
determination should be done prior to each dose of Etoposide. 
Renal Impairment: In patients with impaired renal function, the initial dose 
modification should be considered based on measured creatinine clearance. 
21. Brand names : 
 
 Eposin 
 Etopophos 
 Lastet 
 Toposar 
 Vepesid 
 Vepesid J 
 Zuyeyidal 
 
22. Storage:  Store protected from moisture. 
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2.3.1. CHOLESTEROL:                                    (USP, 2009; Raymond C. R., 2006) 
 
1. Nonproprietary Names: 
 
 BP: Cholesterol 
 JP: Cholesterol 
 PhEur: Cholesterolum 
 USPNF: Cholesterol 
 
2. Synonyms              : Cholesterin; cholesterolum. 
 
3. Chemical Name and CAS Registry Number : Cholest-5-en-3b-ol [57-88-5] 
 
4. Empirical Formula            : C27H46O 
 
5. Molecular Weight               : 386.67 
 
6. Structural Formula : 
  
2.3.EXCIPIENTS PROFILE 
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7. Functional Category: 
 
  Emollient; emulsifying agent. 
 
8. Applications in Pharmaceutical Formulation or Technology: 
 
  Cholesterol is used in cosmetics and topical pharmaceutical formulations at 
concentrations of 0.3–5.0% w/w as an emulsifying agent. It imparts water-absorbing 
power to an ointment and has emollient activity. Cholesterol also has a physiological 
role. It is the major sterol of the higher animals, and it is found in all body tissues, 
especially in the brain and spinal cord. It is also the main constituent of gallstones. 
 
9. Description: 
 
 Cholesterol occurs as white or faintly yellow, almost odorless, pearly leaflets, 
needles, powder, or granules. On prolonged exposure to light and air, cholesterol 
acquires a yellow to tan color. 
 
10. Typical properties: 
 
 Boiling point: 360ºC 
 Density: 1.052 g/cm3 for anhydrous form. 
 Melting point: 147–150ºC 
 Loss on Drying: Not more than 0.3% 
 Residue on ignition: Not more than 0.1% 
 Specific rotation: Between 34º and 38º 
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 Solubility of cholesterol: 
                 Table 2.3: Solubility of cholesterol in various 
S.NO SOLVENT    SOLUBILITY AT 20ºC 
UNLESS AND OTHERWISE        
STATED 
1. Acetone Soluble 
2. Benzene 1 in 7 
3. Chloroform 1 in 4.5 
 
4. 
 
 
Ethanol 
 
1 in 147 at 0ºC 
1 in 78 at 20ºC 
1 in 29 at 40ºC 
1 in 19 at 50ºC 
1 in 13 at 60ºC 
 
 
5. 
 
Ethanol (95%) 
1 in 78 (slowly) 
1 in 3.6 at 80ºC 
6. Ether 1 in 2.8 
7. Hexane 1 in 52 
8. Isopropyl myristate 1 in 19 
 
 
9. 
 
 
Methanol 
 
1 in 294 at 0ºC 
1 in 153 at 20ºC 
1 in 53 at 40ºC 
1 in 34 at 50ºC 
1 in 23 at 60ºC 
 
10. Vegetable oils Soluble 
 
11. Water Practically insoluble 
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11. Method of Manufacture: 
 
  The commercial material is normally obtained from the spinal cord of cattle by 
extraction with petroleum ethers, but it may also be obtained from wool fat. 
Purification is normally accomplished by repeated bromination. Cholesterol may also 
be produced by entirely synthetic means. Cholesterol produced from animal organs 
will always contain cholestanol and other saturated sterols. 
 
12. Stability and Storage Conditions: 
 
  Cholesterol is stable and should be stored in a well-closed container, protected 
from light. 
 
2.3.2. POLYSORBATE 80:                           (USP, 2009; Raymond C. R., 2006) 
 
1. Definition: 
 
   Mixture of partial esters of fatty acids, mainly Oleic acid (0799), with 
sorbitol and its anhydrides ethoxylated with approximately 20 moles of ethylene 
oxide for each mole ofsorbitol and sorbitol anhydrides. 
 
2. Nonproprietary Names: 
 
 BP:  Polysorbate 80 
 JP: Polysorbate 80 
 PhEur: Polysorbatum 80 
 USPNF:  Polysorbate 80. 
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3. Synonyms: 
 
  Atlas E; Armotan PMO 20; Capmul POE-O; Cremophor PS 80; Crillet 4; 
Crillet 50; Drewmulse POE-SMO; Drewpone 80K; Durfax 80; Durfax 80K; E433; 
Emrite 6120; Eumulgin SMO; Glycosperse O-20; Hodag PSMO-20; Liposorb O-20; 
Liposorb O-20K; Montanox 80; polyoxyethylene 20 oleate; Protasorb O-20; Ritabate 
80; (Z)-sorbitan mono-9-octadecenoate poly(oxy1,2-ethanediyl) derivatives; Tego 
SMO 80; Tego SMO 80V; Tween 80. 
 
4. Chemical Name and CAS Registry Numbers: 
 
   Polyoxyethylene 20 sorbitan monooleate and [9005-65-6] 
 
5. Empirical Formula : C64H124O26 
 
6. Molecular Weight  : 1310 
 
7. Structural formula: 
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8. Functional Category: 
 
Emulsifying agent; nonionic surfactant; solubilizing agent; wetting, 
dispersing/suspending agent. 
 
9. Description: 
 Appearance: Oily, yellowish or brownish-yellow, clear or slightly 
opalescent, liquid. 
 Odor: Characteristic odor and a warm. 
 Taste: Somewhat bitter taste. 
 
10. Typical properties: 
 
 Acidity/alkalinity  : pH = 6.0–8.0 for a 5% w/v aqueous 
                                                  solution. 
 Flash point   : 149ºC 
 Acid value (%)  :  2.0 
 Hydroxyl value  :  65-80 
 Moisture content  :  3.0 
 Saponification value  :  45-55 
 HLB value   :  15.0 
 Specific gravity at 25ºC : 1.08 
 Viscosity (mPa s)  :  425 
 Surface tension at 20ºC (mN/m): 42.5 
 Heavy metals   :  0.001% 
 Total ash   :  Maximum 0.25 per cent 
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 Solubility: 
• Dispersible in water, in anhydrous ethanol, in ethyl acetate and in 
methanol. Practically insoluble in fatty oils and in liquid paraffin. 
 
11. Method of Manufacture: 
   Polysorbates are prepared from sorbitol in a three-step process. Water is 
initially removed from the sorbitol to form a sorbitan (a cyclic sorbitol anhydride). 
The sorbitan is then partially esterified with a fatty acid, such as oleic or stearic 
acid, to yield a hexitan ester. Finally, ethylene oxide is chemically added in the 
presence of a catalyst to yield the polysorbate. 
 
12. Applications in Pharmaceutical Formulation or Technology: 
 
Polysorbate 80 is an excipient that is used to stabilize aqueous 
formulations of medications for parenteral administration, and used as an 
emulsifier in the manufacture of the popular anti-arrhythmic amiodarone. It is also 
used as an excipient in some European and Canadian influenza vaccines. They 
have been found to be useful in improving the oral bioavailability of drug 
molecules that are substrates for p-glycoprotein. Polysorbates are also widely used 
in cosmetics and food products. 
 
13. Stability and Storage Conditions: 
 
 
Polysorbates should be stored in a well-closed container, protected from 
light, in a cool, dry place. 
  
 
 
Aim  
&  
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3. AIM AND OBJECTIVE 
 
The concept of drug delivery to a particular site for the treatment of localized 
disease in the body and thereby decreasing adverse effect of drug with improving its 
therapeutic index is being considered as a challenge in modern formulation design. 
So, constant efforts have been persued in order to design such an ideal drug delivery 
system which improves therapeutic index of drugs and also improves patient 
compliance. One such area which has attracted increasing attention of pharmaceutical 
scientist and has shown very promising results is “Target oriented Drug Delivery 
System”. 
Amongst all carriers utilized for target oriented drug delivery, vesicular drug 
delivery system in form of liposomes and niosomes are most extensively investigated. 
Vesicular drug delivery systems such as liposomes and niosomes have been claimed 
to prolong and control the action of drug.  
There are problems in the general applications of liposomes. They have 
problems regarding degradation due to instability of phospholipid molecules and cost 
of production is high. One alternative of phospholipids is the hydrated mixture of 
cholesterol and nonionic surfactants. This mixture provides vesicles known as 
niosomes or non-ionic surfactant vesicles. Thus Niosomes have been proved to be 
versatile carrier for wide variety of drug. 
 
Niosome has been regarded as a beneficial carrier system for parental 
application of variety of drugs due to their biocompatible and biodegradable 
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properties. And there is an increase in their circulation time. Longer circulation of 
Niosome in blood resulted in higher uptake of drug in tumor.  
Etoposide is a semi synthetic derivative of podophyllotoxin that exhibits anti 
tumor activity. A Etoposide is first line treatment in patient with small cell lung 
cancer & requiring the treatment over a prolonged period of time. Etoposide when 
loaded into niosomes could release the drug over a long period of time. Etoposide 
encapsulation by niosomal drug delivery system is to reduce the dosing frequency as 
well as patient compliance. 
 In present work an attempt was made to prepare the niosomes of Etoposide 
can continuously deliver therapeutically significance of drug for prolonged time 
period. To study the effect of variable on niosome performance and characteristic 
different batches need to be prepared by implementing 32 factorial designs. 
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 4. PLAN OF WORK 
 
1. LITERATURE  REVIEW 
2. SELECTION OF DRUG AND EXCIPIENTS 
3. PROCUREMENT OF DRUG AND EXCIPIENTS 
4. EXPERIMENTAL WORK 
 PREFORMULATION STUDIES 
 Identification of Drug 
 Organoleptic Properties 
 Determination of Melting Point 
 Solubility Study 
 FTIR 
 UV Spectrophotometric Study 
o Determination  of λmax 
o Development  of standard curve of Etoposide 
 Loss on drying 
 Assay of Etoposide 
 
 FORMULATION DESIGNING BY 32 FULL FACTORIAL DESIGN 
 FORMULATION OF NOVEL NIOSOMAL DELIVERY SYSTEM 
 EVALUATION OF NIOSOMES 
 Determination of niosomes recovery (%), entrapment efficiency (%EE) 
and drug loading efficiency (%LE) 
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 Shape and surface morphology 
 Analysis of vesicle size and polydispersity index 
 Determination of vesicle surface charge (Zeta potential) 
 Compatibility study by FTIR and DSC analysis 
 In-vitro drug release studies 
 Kinetic of in-vitro drug release 
 Sterilization technique  
 Test for sterility  
 In-vivo drug targeting studies 
 Stability studies 
5. RESULTS AND DISCUSSION 
6. SUMMARY AND CONCLUSION 
7. FUTURE PROSPECTS 
8. BIBLIOGRAPHY 
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5. MATERIALS AND EQUIPMENTS 
 
5.1. MATERIALS USED: 
 
 
Table 5.1: List of Drug and Excipients with source  
 
 
S.No. Ingredients Supplier 
1 Etoposide Strides Arco lab, Bangalore. 
2 Cholesterol  Loba Chemie Pvt. Ltd., Mumbai. 
3 Polysorbate 80 S D fine-chem limited, Mumbai. 
4 Chloroform Loba Chemie Pvt. Ltd., Mumbai. 
5 Diethyl ether Loba Chemie Pvt. Ltd., Mumbai. 
6 Hydrochloric acid S D fine-chem limited, Mumbai. 
7 Disodium hydrogen phosphate S D fine-chem limited, Mumbai. 
8 Potassium dihydrogen phosphate Qualigens fine chemicals, Mumbai. 
9 Sodium hydroxide S D fine-chem limited, Mumbai 
10 Sodium chloride Qualigens fine chemicals, Mumbai. 
11 Dialysis bag Himedia labaratories, Mumbai. 
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5.2.  EQUIPMENTS USED: 
 
Table 5.2: List of Equipments with model/make 
 
S.No Equipments Model/ Make 
1. Electronic balance Shimadzu BL-220H 
2. Magnetic stirrer 1-MLH, remi equipments limited, vasai 
3. Freeze drying apparatus LYPHLOCK; Labconco, Kansas City, MO 
4. Scanning electron microscope FEI Quanta FEG 200 HR- SEM 
5. Zeta potential Zetasizer , Malvern, UK 
6. Photon correlation spectroscopy Malvern instruments, UK 
7. pHmeter  LI120 pHmeter, ELICO LTD  
8. Humidity chamber Labtech 
9. Micro centrifuge RM-12C, Remi equipments limited, vasai 
10. Homogenizer Remi equipments limited, vasai 
11. UV Visible spectrophotometer 
Shimadzu-1700 Pharmaspec  
UV-visible spectrophotometer, Elico 
12. FTIR spectrophotometer Shimadzu FTIR-801 spectrophotometer 
13. Differential scanning calorimeter Shimadzu  DSC W70 
14. Melting point apparatus Guna enterprises, Chennai 
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         STUDIES 
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6. PREFORMULATION STUDY 
 
6.1. Identification of Drug: 
 
The preliminary studies were carried out by testing of different physical and 
chemical properties of drug as follows.  
 
6.1.1. Organoleptic properties:                                      
                                     
The Organoleptic properties like physical state, color, odor etc., of the drug 
was reported with help of the descriptive terminology. It helps to identify the       
drug. 
 
6.1.2. Melting point:                                                                                   (IP, 2007) 
 
It is the easy way to identify the drug. The melting point of Etoposide was 
tested by use of a laboratory melting point apparatus with a procedure given in the 
Indian Pharmacopeia 2007. 
 
6.1.3. Solubility study:                                                                                (IP, 2007) 
 
The solubility of Etoposide was determined by micropipette method in various 
solvents in order to meet the official standards. The solubility of drug was recorded by 
using various descriptive terminology specified in Indian pharmacopoeia, 2007. 
    The general description of solubility as per Indian Pharmacopoeia was listed 
out in the Table 6.1.                     
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                               Table 6.1: Description of solubility 
Descriptive term Parts of solvent required for 1 part of 
solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1,000 
Very slightly soluble From 1,000 to 10,000 
Practically insoluble Greater than or equal to 10,000 
 
6.1.4. FTIR spectroscopy:                     (Skoog D.A., et al., 1996; IP, 2007) 
 
The infrared spectrum was generally used as an identification parameter to 
know the chemical structure of drugs. For the FTIR spectrum of Etoposide FTIR 
spectrophotometer was used.  
A small quantity of sample was mixed with sufficient potassium bromide and 
compressed into a pellet by applying a 10 tons pressure with help of a hand operated 
press. This pellet was kept in a sample holder and scanned from 4000 to 400 cm-1. 
The absorption maximums in spectrum obtained with the substance being examined 
correspond in position and relative intensity to those in the reference spectrum.  
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6.1.5. UV Spectrophotometric Study:  
6.1.5.1. Determination of λ max:                  
The absorption maximum of the standard solution was scanned between 200-
400 nm regions on Shimadzu-1700 Pharmaspec UV-visible spectrophotometer. The 
absorption maximum obtained with the substance being examined corresponds in 
position and relative intensity to those in the reference spectrum. 
 
6.1.5.2. Development of standard curve of Etoposide in methanol: 
 Preparation of stock solution: 
Accurately weighed 25 mg of etoposide was dissolved in little quantity of 
methanol and volume was adjusted to 25 mL with the same to prepare standard 
solution having concentration of 1000 µg/ mL. From this 10 mL was pipette out and 
made up to 100 mL with methanol to produce 100 µg/mL. 
 
 Procedure: 
 From the stock solution, aliquots of 2, 4, 6, 8 and 10 mL were transferred to 
10 mL volumetric flasks and final volume was made to 10 mL with methanol to get 
20 to 100 µg/mL. Absorbance values of these solutions were measured against blank 
(methanol) at 284 nm using UV-visible spectrophotometer. 
 
6.1.5.3. Development of standard curve of Etoposide:   
 Preparation of phosphate buffer saline pH 7.4: 
Phosphate buffer saline pH 7.4 was prepared according to I.P. 2007. A 
quantity of 2.38g disodium hydrogen phosphate, 0.19g potassium dihydrogen 
phosphate and 8.0g sodium hydroxide was diluted with fresh distilled water to 
produce 1000 mL. 
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 Preparation of stock solution of Etoposide in PBS pH 7.4 solution: 
  
Accurately weighed 25 mg of etoposide was dissolved in little quantity of 
phosphate buffer saline solution pH 7.4 and volume was adjusted to 25 mL with the 
same to prepare standard solution having concentration of 1000 µg/ mL. From this 10 
mL was pipette out and made up to 100 mL with PBS pH  to produce 100 µg/mL. 
 
 Procedure: 
 
 From the stock solution, aliquots of 2, 4, 6, 8 and 10 mL were transferred to 10 
mL volumetric flasks and final volume was made to 10 mL with pH 7.4 phosphate 
buffer saline to get 20 to 100 µg/mL. Absorbance values of these solutions were 
measured against blank (phosphate buffer saline pH 7.4) at 284 nm using UV-visible 
spectrophotometer.  
 
6.1.6. Loss on drying:                                                                                                                            (IP, 2007) 
 
Loss on drying is the loss of weight expressed as percentage w/w resulting 
from water and volatile matter of any kind that can be driven off under specified 
condition. The accurately weighed 1gm of sample was transferred in glass-stoppered, 
shallow weighing bottle and accurately weighed the bottle. The bottle was transferred 
in oven and substance was dried at 105°C for 4 hours. The bottle was removed from 
oven and reweighed; loss on drying was calculated by following equation, 
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6.1.7. Assay of Etoposide: 
Accurately weighed 10 mg of etoposide was dissolved in little quantity of 
methanol and volume was adjusted to 100 mL with the same to prepare standard 
solution having concentration of 100 µg/mL. From the above solution, aliquots of 6 
mL were transferred to 10 mL volumetric flasks and final volume was made to 10 mL 
with methanol. Absorbance values of these solutions were measured against blank 
(methanol) at 285 nm using Shimadzu-1700 Pharmaspec UV-visible 
spectrophotometer. The percentage purity of drug was calculated by using calibration 
graph method (least square method).  
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7.  FORMULATION OF  NOVEL NIOSOMAL DELIVERY SYSTEM 
 
7.1. Designing the formula: 
 (Vyas Jigar, et al., 2011; Farhan J. Ahmad, et al., 2011; Ismail Mouzam, et al., 2011) 
 Niosomes were designed by 32 full factorial design to study the interaction 
variables of formulation on characterization of niosomes. Amount of polysobate 80 
and cholesterol were selected as independent variable. Amount of Etoposide (10mg) 
were kept constant. The variables and the level of each factor were shown in table 7.1.  
Table 7.1:   Variables in 32 full factorial design 
 
Each row identifies an experiment and each row provides a result (response). 
The levels of factors studied were chosen that the irrelative difference was adequate to 
have a measurable effect on response, along with the information that the selected 
 
Independent  variable 
factors 
                                
                               Levels used 
 
Lower (-1) 
 
Middle (0) 
 
Upper (+1) 
 
Polysorbate 80 (X1) mg 
 
5 
 
 
10 
 
 
15 
 
 
Cholesterol (X2) mg 
 
5 
 
10 
 
15 
 
Dependent variable, response 
Y= Entrapment efficiency 
   
                   Amount of drug used was 10 mg in all formulation 
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levels are within practical use. The formulation of the factorial design is represented 
in table 7.2. 
                
              Table 7.2:  Designing the formulation with a 32 full factorial design   
 
S.NO 
 
Code of 
formulation 
 
     Polysorbate 80        
concentration (X1) 
 
          Cholesterol           
concentration (X2) 
1 EN1 -1 (5mg) -1 (5mg) 
2 EN2 -1 (5mg) 0 (10mg) 
3 EN3 -1 (5mg) +1 (15mg) 
4 EN4 0 (10mg) -1 (5mg) 
5 EN5 0 (10mg) 0 (10mg) 
6 EN6 0 (10mg) +1 (15mg) 
7 EN7 +1 (15mg) -1 (5mg) 
8 EN8 +1 (15mg) 0 (10mg) 
9 EN9 +1 (15mg) +1 (15mg) 
 
PREPARATION OF NOVEL NIOSOMAL DELIVERY SYSTEM: 
                                                      (Balasubramanian A., et al., 2002) 
The Novel niosomal delivery system was prepared by the modification of 
reverse phase evaporation technique [REV].  Polysorbate 80 and cholesterol were 
dissolved in a mixture of diethyl ether and chloroform.  
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Etoposide was dissolved in the lipid solution. The organic phase was the 
added to the aqueaes phase (phosphate buffer saline pH 7.4). The resulting two phase 
system was homogenized using a homogenize [REMI] for 3 minutes at 8000 rpm. 
 The organic phase was removed at 40ºc under reduced pressure. The reduced 
suspension was further homogenized for 1 min. The suspension was then heated on a 
water bath at 60ºc for 10 min to yield the niosomes. 
 The unentrapped was removed by centrifugation of dispersion at 14,000 rpm 
for 60 min in a centrifuge. The supernatant was removed and the pellet (residue) was 
resuspended in PBS pH 7.4. 
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8. EVALUATION OF NIOSOMES 
 
8.1. Determination of niosomes recovery (%), entrapment efficiency (%EE) and 
drug loading efficiency (%LE): 
                                                                                      (Kumar Abhinav, et al., 2011) 
To determine niosome recovery, entrapment efficiency and drug loading 
efficiency, the niosomal aqueous suspension was ultracentrifuged at 3000 rpm for 5 
min, supernatant was removed and sediment was washed twice with distilled water in 
order to remove the adsorbed drug.  
The niosomal recovery (%) was calculated as:  
    Amount of niosomes recovered                                       
Niosomes recovery (%) =  X 100 
    Amount of drug + excipients 
 
The entrapment efficiency (%EE) was calculated using formula:  
          Amount of drug in niosomes 
Entrapment efficiency (%) =    X 100 
     Amount of drug used 
The drug loading efficiency (%LE) was calculated as:  
       Amount of drug in niosomes 
      Drug loading efficiency (%) =  X 100 
                                     Amount of niosomes recovered                                       
 
8.2. Shape and surface morphology:                                (Vedha Hari B.N., 2011) 
 The morphology of the noisome was studied by scanning electron microscopy 
(FEI Quanta FEG 200 HR- SEM). Samples were prepared by allowing them to air dry 
on an aluminum stub with double- sided adhesive tape. The stub was fixed into a 
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simple holder and placed in the vacuum chamber of scanning electron microscope and 
randomly scanned for surface morphology. 
8.3.  Analysis of vesicle size and polydispersity index:           
                (Sandeep Kumar Sharma, et al., 2009; Ismail Mouzam, et al., 2011)                                        
The size analysis of niosomes was performed by laser scattering method. The 
z- average diameter of prepared vesicle was determined dynamic light scattering 
using a Zetasizer, (Zetasizer nano-zs ZEN3600; Malvern Instrument, Worcestershire, 
UK). For the measurement, 100µl of the formulation was diluted with an appropriate 
volume of PBS pH 7.4 and vesicle diameter and polydispersity index were determined. 
8.4. Determination of vesicle surface charge (Zeta potential):  
            (Varaporn Buraphacheep Junyaprasert, et al., 2008) 
 The charge on vesicles is expressed in terms of zeta potential. The vesicle 
surface charge can play an important role in the behavior of niosomes in vivo and in 
vivo. In general, charged niosomes are more stable against aggregation and fusion 
than uncharged vesicles. In order to obtain an estimate of the surface potential, the 
zeta potential of individual niosomes can be measured by Zetasizer. Zeta potential of 
niosomes was measured in a Zetasizer ZEN3600 (Malvern instruments, UK). The 
niosomes were dispersed in phosphate- buffered saline (pH 7.4), and the zeta potential 
was determined.  
8.5. Compatibility study:     
8.5.1 Compatibility studies by Fourier transform infrared Spectroscopy (FTIR):  
               (Pandey shivanand, et al., 2010) 
FTIR study was carried out to check compatibility of drug with surfactant and 
cholesterol. The interaction between drug substance, surfactants and cholesterol of 
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best formulations were evaluated by comparing the IR spectrum of pure drug sample. 
Infrared spectrum of etoposide was determined on Fourier transform infrared 
spectrophotometer using potassium bromide dispersion method. The base line 
correction was done using dried potassium bromide. Then the spectrum of dried 
mixture of drug and potassium bromide was run followed by drug loaded noisome. 
Infrared (IR) spectra of the formulation were recorded between 400 and 4000 cm-1.  
The spectra of drug and other ingredients in the formulations were compared with that 
of the original spectra. 
8.5.2. Compatibility studies by Differential scanning calorimetry (DSC): 
                                            (Y. Prasanna raju, et al., 2007) 
The interaction between drug substance, surfactants and cholesterol of best 
formulations were evaluated by comparing the IR spectrum of pure drug sample. 
Thermograms of the pure drug Etopside and drug loaded niosomes were analysed 
using a Differential scanning calorimeter (Shimadzu W70 thermal analyzer). The 
samples were heated in a hermetically sealed aluminum pans in the temperature range 
of 100-300ºC at heating rate of 10ºC /min under nitrogen flow of 30ml/min.  
 
8.6. In-vitro release studies:                    
                              (Anand Kumar Y., et al., 2010; Kandasamy Ruckmani, et al., 2010) 
In vitro release was studied using a dialysis bag (Dialysis membrane, 12,000 - 
14,000 molecular weight cut off) as a donor compartment. Niosomes containing 
entrapped etoposide obtained after configuration of 2 ml of the formulation were 
resuspended in 1ml of PBS pH 7.4, and used for the release study. The dialysis 
membrane was soaked in warm water for 10 minutes, one end sealed with a clip, the 
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noisome preparation or plain etoposide solution was pipette into the bag and the bag 
was sealed with another closure clip for to prevent leakage. The dialysis bag was 
placed in 100 ml of PBS, pH 7.4, at 37 ± 2ºC. The medium, which acted as the 
receptor compartment, was stirred at 100 rpm. Samples of medium (5 ml) were 
withdrawn hourly and replaced with fresh buffer and etoposide absorbance at 284 nm 
was measured using PBS as blank. Results were the mean values of three runs.  
           
                                         Dialysis membrane 
                
                        Dialysis bag                                   Magnetic stirrer with thermostat 
                     Figure 8.1:  Schematic assembly of In-vitro release study  
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8.7. Kinetics of In-vitro drug release:                          
                                              (Brahmankar D.M., 2006; Anupriya kapoor, et al., 2011) 
To study the release kinetics of in-vitro drug release, data was applied to 
kinetic models such as zero order, first order, Higuchi and Korsmeyer- Peppas. 
 Zero order: 
 
Where K0 - is the zero-order rate constant expressed in units of 
concentration/time   
                          t -is the time in hrs. 
 First order: 
 
Where   C0 - is the initial concentration of drug, 
   
                         K - is the first order constant 
                 t - is the time in hrs.  
 Higuchi: 
 
                    Where   Qt - is the amount of the release drug in time t, 
                  K- is the kinetic constant and  
                           t- is time in hrs. 
 
                                                                                    
LogC = LogC0 – Kt / 2.303                                                                            
Qt = Kt1/2                                                                                                         
C = K0t                                                                                                              
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 Korsmeyer Peppas: 
 
 
       Where   Mt - represents amount of the released drug at time t,  
                    M∞- is the overall amount of the drug (whole dose) released after 12 hrs  
                    K- is the diffusional characteristic of drug/ polymer system constant  
                    n- is a diffusional exponent that characterizes the mechanism of release 
of drug.  
The value of n indicates the drug release mechanism related to the geometrical 
shape of the delivery system, if the exponent n = 0.5, then the drug release mechanism 
is Fickian diffusion. If n < 0.5 the mechanism is quasi-Fickian diffusion, and  0.5 < n 
< 1.0, then it is non-Fickian or anomalous diffusion and when n = 1.0 mechanism is 
non Fickian case II diffusion, n> 1.0 mechanism is non Fickian super case II. 
 
8.8. Sterilization technique:        
 The formulated Etoposide noisomes were sterilized by membrane filtration 
(Mechanical method) using membrane filter with pore size of 0.22 µm in an aseptic 
condition using laminar air flow. All glass containers were sterilized by autoclave, 
115-120 ºC at 30 min (Moist heat Sterilization).  
 
8.8.1. Test for sterility:         (IP, 2007) 
 
Sterility tests were based upon the principle that if bacteria or fungi are placed 
in a medium which provided nutritive material, moisture, and the desired pH and kept 
Mt / M∞ = Kt n                                                                                             
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at a favorable temperature, the organism will grow and their presence can be indicated 
by the growth in originally medium. 
The tests for sterility were done by detecting the presence of viable forms of 
bacteria, fungi and yeast in or on preparations. The tests were carried out under strict 
aseptic techniques in order to avoid accidental contamination of the preparation. 
Sterility test for niosomes: 
 The niosomes were subjected to sterility test. The test for sterility was 
intended for detecting the presence of viable forms of bacteria, fungi, and yeast in 
preparations. The tests were carried out under aseptic conditions to avoid 
contamination of the product during the test. 
Culture media: 
For anaerobic bacteria and fungi: 
 Medium: Soyabean casein medium. 
This medium can be used for the detection of anaerobic bacteria and fungi. 
Preparation of soyabean casein medium:   
   Table 7.5: Preparation of soyabean casein medium 
  
 
 
 
 
S.No. Ingredients Quantity 
1 Pancreatic digest of casein 17.0 g 
2 Papic digest of soyabean 3.0 g 
3 Meat 5.0 g 
4 Sodium chloride 2.5 g 
5 Dibasic potassium phosphate 2.5 g 
6 Dextrose 2.5 g 
7 Distilled water 1000 mL 
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The above ingredients were dissolved completely in 1000 mL of distilled 
water and the medium was boiled for 10 minutes. The pH was adjusted to 7.3 ± 0.2. 
Media was distributed into 9 cm diameter petri dishes  
Sterilization of medium: 
 Anaerobic culture medium was sterilized by autoclaving at a pressure of       
15 lbs/in² and at a temperature of 121ºC for 15 minutes. Autoclaved medium should 
be kept in room temperature before inoculation of the sample. 
Incubation: 
 The sterilized niosomal formulation were placed in to fluid thioglycollate 
medium and incubated at 20ºC - 25ºC for not less than seven days. 
 At intervals during the incubation period, the media were examined visually 
for microbial growth. 
 
Control test 
 In order to support the above performed test, a negative control test was also 
carried out for quality control maintenance. 
 Negative control test was carried out in order to confirm that the media and the 
environment provided for incubation were suitable for the growth of micro organism. 
8.9. In vivo drug targeting studies:    
                    (Lakshmi P.K. and Shyamala Bhaskaran, 2009; Doijad R.C., et al., 2008) 
 
To perform this animal studies, protocol was submitted and received 
permission from Institutional Animal Ethics Committee (Approval No. 409/01/a 
CPCSEA dated on 22.07.2011).   
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Best formulation was selected on the basis of In-vitro release study. Selected 
formulation was sterilized in UV radiations. Sterilized niosomal formulation was 
employed for In-vivo tissue distribution study. 
Albino mice are used for this test because of uniform breed as the result the 
variability factor in the experimentation is reduced, economic and easily available. 
Also, using mice is cost effective.  
To perform this study, the followings were selected,                       
Animal:  Mice 
Species:   Albino 
Gender:   Either sex 
Number of animals:  Ten 
Weight:  20-25 g 
  
Ten healthy mice weighing 20-25gms were selected. The animals were fasted 
for 12 hours by maintaining a constant day and night cycle. Mice of either sex were 
divided into two groups each containing five mice. After redispersing the Etoposide 
loaded niosomes in phosphate buffer saline (pH 7.4) were administered intravenously 
in the tail vein of group I and the plain Etoposide were given intravenously to group II 
at a dose of 1.3mg/kg.  
The mice were sacrificed after 12 hours by giving anesthetic ether and the 
organs like liver, lungs, spleen, kidney and brain was isolated, homogenized 
separately and centrifuged at 15,000 rpm to obtain the supernatant. Further it was 
filtered through a membrane filter with pore size of 0.22 µm. The drug content was 
estimated using UV- spectrophotometer at 284nm. 
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                      Tail vein injection                                   Sacrificed after 12 hours  
       
                                                 Mice skin were cut opened                        
           
                                Isolation of brain 
                   Figure 8.2: Sequence of process involved in isolation of organs                                                                                                                                       
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                            Secluded Liver                                        Secluded Spleen 
                                   
                                                      Secluded Kidney 
                
                  Secluded Lungs                                                Secluded Brain 
                                  Figure 8.3: Collective display of isolated organs 
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8.10. Stability studies:               (Manavalan R and Ramasamy S., 2004) 
 
Stability is defined as the capacity of a drug substance or drug product to 
remain within established specifications to maintain its identity, strength, quality, and 
purity throughout the retest or expiration dating periods (FDA, 1998). 
Stability of pharmaceutical preparation can be defined as the capability of 
particular formulation (dosage form) in a specific container/closure system to remain 
within its physical, chemical, microbiological, therapeutic and toxicology 
specifications throughout its shelf life. 
 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted. The International Conference on Harmonization (ICH) 
Guidelines titled “Stability testing of New Drug Substances and Products” describes 
the stability test requirements for drug registration application in the European Union, 
Japan and the States of America. 
 
ICH specifies the length of study and storage conditions 
 Long-Term Testing: 25°C ± 2°C at 60% RH ± 5% for 12 Months 
 Accelerated Testing: 40°C ±2°C at 75% RH ± 5% for 6 Months 
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Procedure:                                            
                                         (Doijad R.C., et al., 2008; Pandey Shivanand., et al., 2010) 
 
The optimized formulation EN5 was subjected to stability testing upto 3 
months at refrigerator temperature, room temperature and elevated condition (4
0 
C ±1
0 
C , 250± 2
0 
C at 60% RH±5% RH and 400
 
C ±2
0 
C at 75% RH ±5% RH ).  The 
samples were withdrawn after periods of 1st month, 2nd month and 3rd month. The 
samples were analyzed for its parameters such as, 
 
• Percentage drug retained  
• In-vitro drug release 
• Test for sterility 
 
  
.  
  
 
 
 
 
Results 
And 
Discussion 
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9. RESULTS AND DISCUSSION 
 
9.1. Identification of Drug: 
  
9.1.1. Organoleptic Properties: 
 Colour           : white 
 Odour            :  Odorless 
 Appearance    : Crystalline powder 
9.1.2. Melting Point: 
Melting point of Etoposide was found to be 250.6 ºC. The official melting 
point range for Etoposide is between 236-251°C. Hence, results were complied the 
limits specified in official Book. 
9.1.3. Solubility Study: 
Table 9.1: The solubility of Etoposide in various solvents              
 
 
 
 
 
 
 
 
 
 
 
S.No Name of solvent  Solubility 
1. Water Sparingly soluble 
2. 0.1NHCl Sparingly soluble 
3. Diethyl ether Sparingly soluble 
4. Ethanol Slightly soluble 
5. Methanol Very soluble 
6. Chloroform Very soluble 
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9.1.4. FTIR spectroscopy: 
The FTIR spectrum of Etoposide was shown in Figure 9.1 and the 
interpretations of IR frequencies were showed in Table 9.2. 
 
 
Fig.9.1: FTIR spectrum of Etoposide 
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Table 9.2: Characteristic Frequencies in FTIR spectrum of Etoposide 
S.No. Transition IR Range (cm-1) 
Absorption wave 
number of Etoposide 
(cm-1) 
1 O-H stretching  3400 – 3200 3452.44 
2 CH3 stretching  2930 – 2920 2920.63 
3 C=O stretching  1780 - 1760 1763.39 
4 C=C stretching  1660-1610 1614.67 
5 C-C stretching 1580-1500 1505.65 
6 COO stretching 1430-1300 1425.1 
7 O-H stretching 1380-1280 1335.75 
8 C-O stretching 1300-1200 1284.35 
9 C-O-C stretching 1150-1100 1116.83 
10 C-O stretching 1075-1190 1074.95 
11 C-H bending 995-985 993.55 
12 C-H bending 860-900 882.88 
13 C-C bending 680-725 682 
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Interpretation of FTIR Spectrum: 
 
Major functional groups present in Etoposide show characteristic peaks in IR 
spectrum. Table 9.1 shows peaks observed at different wave numbers and the 
functional group associated with these peaks. The major peaks are identical to 
functional group of Etoposide. Hence, the sample was confirmed as Etoposide. 
9.1.5. UV Spectrophotometric Study: 
 The absorption maximum for Etoposide in methanol was found to be 285 nm 
 
 
Fig. 9.2: λmax of Etoposide in methanol 
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 The absorption maximum for Etoposide   in PBS  pH 7.4 was found to be  284 nm 
 
Fig. 9.3: λmax of Etoposide in PBS pH 7.4 
9.1.6. Calibration curve of Etoposide in methanol: 
UV absorption spectrum of Etoposide in methanol showed λ max at 285 nm. 
Absorbance obtained for various concentrations of etoposide in methanol were given 
in Table 9.3. The graph of absorbance vs concentration for Etoposide was found to be 
linear in the concentration range of 20-100 µg /mL. The drug obeys Beer- Lambert’s 
law in the range of 20-100 µg /mL. 
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       Table 9.3: Data of concentration and absorbance for Etoposide in methanol. 
 
S.No. Concentration 
(µg/mL) 
Absorbance 
1 0 0.0000 
2 20 0.139 
3 40 0.275 
4 60 0.416 
5 80 0.561 
6 100 0.714 
 
   
          
Fig. 9.4: Standard graph of Etoposide in methanol  
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Table 9.4:  Data for Calibration Curve Parameters 
S.No. Parameters  Values  
1 Correlation coefficient (r) 0.9997 
2 Slope (m) 0.0071 
3 Intercept (c) -0.0098 
 
9.1.7. Calibration Curve of Etoposide in PBS PH 7.4: 
UV absorption spectrum of Etoposide in PBS pH 7.4 showed λ max at 284 nm. 
Absorbance obtained for various concentrations of etoposide in methanol were given 
in Table 9.5. The graph of absorbance vs concentration for etoposide was found to be 
linear in the concentration range of 20-100 µg /mL. The drug obeys Beer- Lambert’s 
law in the range of 20-100 µg /mL. 
         Table 9.5: Data of concentration and absorbance for Etoposide in PBS pH 7.4 
 
S.No. Concentration 
(µg/mL) 
Absorbance 
1 0 0.0000 
2 20 0.165 
3 40 0.318 
4 60 0.486 
5 80 0.649 
6 100 0.798 
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                          Fig. 9.5: Standard graph of Etoposide in PBS pH 7.4. 
Table 9.6:  Data for Calibration Curve Parameters 
S.No. Parameters  Values  
1 Correlation coefficient (r) 0.9998 
2 Slope (m) 0.00798 
3 Intercept (c) 0.0041 
 
9.1.8. Assay of Etoposide: 
The percentage purity of drug was calculated by using calibration graph 
method. The values were recorded in the table 9.7. 
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                          Table 9.7:  Assay of Etoposide 
  
 
 
 
 
 
 
 
The official percentage purity of Etoposide is not less than 95% and not more 
than 105%. So, it can be declared as pure drug. The percentage purity of raw material 
Etoposide was found to be 99.15±0.584. Hence, the sample declared as pure.  
9.2. Evaluation of Niosomes: 
9.2.1. Determination of niosomes recovery (%), entrapment efficiency (%EE) 
and drug loading efficiency (%LE): 
     The results were shown in table 9.8 and figure.9.6. It is revealed that the 
highest % Recovery, %EE and %LE in the niosomes preparation were obtained. 
 The entrapment efficiency of nine batches of etoposide niosomes are recorded 
in Table 9.8. As the cholesterol concentration was increased the encapsulation 
efficiency was increased. The result indicates the cholesterol concentration plays a 
major role in drug entrapment efficiency rather than the surfactant concentration. The 
maximum entrapment efficiency was found in EN5 with 92.1%. The preparation 
parameters, such as cholesterol and surfactant concentrations were modified to obtain 
niosomes with higher entrapment efficiency. 
S.No. Percentage purity 
(%) 
Average percentage 
purity (%) 
1 98.60  
99.15±0.584 
2 99.07 
3 99.77 
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Table 9.8: % Recovery, % EE and % LE of Etoposide niosomes 
 
S. 
No 
 
Formulation 
code 
                                    
Parameter 
Niosomes 
recovery (%) 
Entrapment 
efficiency (%) 
Loading 
efficiency (%) 
 
1. 
 
EN1 
 
69.5 
 
63.2 
 
45.32 
 
2. 
 
EN2 
 
63.20 
 
71.1 
 
44.93 
 
3. 
 
EN3 
 
65.33 
 
86.2 
 
43.88 
 
4. 
 
EN4 
 
58.36 
 
65.0 
 
44.52 
 
5. 
 
EN5 
 
67.66 
 
92.1 
 
45.32 
 
6. 
 
EN6 
 
68.51 
 
84.01 
 
35.08 
 
7. 
 
EN7 
 
59.36 
 
63.2 
 
35.37 
 
8. 
 
EN8 
 
66.31 
 
75.02 
 
32.22 
 
9. 
 
EN9 
 
68.25 
 
90.1 
 
32.97 
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               Fig.9.6: Comparison of entrapment efficiency and loading efficiency  
Novel Niosomal Delivery System of Etoposide                        Results and Discussion 
Adhiparasakthi College of Pharmacy, Melmaruvathur.                                  Page 101 
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  A: polysorbate 80  
  B: cholesterol  
 
                          Fig. 9.7: Quadratic 3D surface plot showing the effect of  
                           Polysorbate 80 and cholesterol on Entrapment efficiency 
 
 Entrapment efficiency was found to be a function of equimolar concentration of 
X1(polysorbate 80) and X2(cholesterol) respectively Fig. 9.7. 
 
9.2.2. Shape and surface morphology: 
Shape and surface morphology of niosomes was studied by Scanning Electron 
Microscopy (SEM) (FEI Quanta FEG 200 HR- SEM). SEM photographs of all 
formulations were shown in Fig. 9.8, 9.9, 9.10 and 9.11.  
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        a) 
   
     b) 
                           Fig.9.8: SEM images of pure Etoposide   
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        a) 
 
       b) 
                                Fig.9.9: SEM images of Formulation EN1 
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        a) 
 
        b) 
                               Fig.9.10: SEM images of formulation EN5 
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         a) 
 
         b) 
                             Fig.9.11: SEM images of Formulation EN9 
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Etoposide niosomes have shown smooth and spherical shape with different 
sizes depending on the ratios of the surfactant and cholesterol used. The bilayered 
structure of the prepared niosomes that exist in disperse or in aggregate collections.  
The photomicrography of pure Etoposide was shown in Fig. 9.8, this showed 
the presence of free crystals in the sample, while the SEM images of Formulated 
noisome showed bilayered structure, spherical shape, smooth surfaces and has no 
evidence of collapsed particles. Smooth surface reveals complete removal of solvent 
from the formulated niosomes and is the indication of good quality 
9.2.3. Analysis of vesicle size and polydispersity index: 
The size distribution reports were shown in Fig. 9.12, 9.13 and 9.14. The size 
distributions along the mean diameter of the niosomes were measured by Dynamic Light 
Scattering Particle Size Analyzer (Malvern instruments).  
Particles of all formulations were in nanosize having smooth spherical surface. 
For formulations EN1, EN5 and EN9 the particle size was found to be 134.6 nm, 
131.4 nm and 136.7 nm respectively. As the surfactant concentration increased there 
was a decrease in particle size may be because of stabilizing effect of the surfactant, 
thereby preventing the aggregation of particles.  
The particle size of niosomes composed of polysorbate 80 and cholesterol 
formulation EN5 in a 1:1 equimolar ratios were 131.4 nm, which was the least when 
compared to other formulations.  
The particle size data showed that niosomes produced were of nanosize and 
had low polydispersity index which indicates relatively narrow particle size 
distribution for all preparations. The polydispersity index (PI) of formulations EN1, 
EN5 and EN9 was found to be 0.707PI, 0.522PI and 0.656PI. 
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          Fig.9.12: Particle size distribution of Formulation EN1 
Novel Niosomal Delivery System of Etoposide                        Results and Discussion 
Adhiparasakthi College of Pharmacy, Melmaruvathur.                                  Page 108 
 
 
 Fig.9.13: Particle size distribution of formulation EN5 
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                Fig.9.14: Particle size distribution of formulation EN9 
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9.2.4. Determination of vesicle surface charge (Zeta potential): 
 
                          Fig.9.15: Zeta potential report of Formulation EN1 
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                          Fig.9.16: Zeta potential report of Formulation EN5 
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                          Fig.9.17: Zeta potential report of Formulation EN9 
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 The stability study of the niosomes was evaluated by measuring the vesicle 
surface charge (zeta potential) of the niosomes by the zeta meter. The zeta potential 
reports were shown in Fig.9.15, 9.16 and 9.17. 
Zeta potential of all formulated niosomes was in the range of −20.2 to – 24.5 
mV which indicates moderate stability with no agglomeration. 
9.2.5. Compatibility study: 
9.2.5.1. By Fourier transform infrared Spectroscopy (FTIR): 
 
                                         Fig.9.18: FTIR spectrum of pure Etoposide 
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                Fig.9.19: FTIR spectrum of Formulation EN5 containing Etoposide with  
                                               Cholesterol and Surfactant  
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        Table 9.9: Major peak observed in FTIR spectrum of pure Etoposide and    
                Etoposide with cholesterol and surfactant used in best formulation. 
 
S.No 
Wave No.  
(cm-1) Functional group 
Peak observed (Yes/No) 
Drug 
Formulation 
EN5 
1 3452.44 O-H stretching Yes Yes 
2 2918.63 CH3 stretching Yes Yes 
3 1764.39 C=O stretching Yes Yes 
4 1614.67 C=C stretching Yes Yes 
5 1505.65 C-C stretching Yes Yes 
6 1425.41 COO stretching Yes Yes 
7 1335.75 O-H stretching Yes Yes 
8 1284.35 C-O stretching Yes Yes 
9 1116.83 C-O-C stretching Yes Yes 
10 1074.95 C-O bending Yes Yes 
11 993.55 C-H bending Yes Yes 
12 882.88 C-H bending Yes yes 
13 682 C-C bending Yes Yes 
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From the FTIR spectral analysis it was found that FTIR spectrum of Etoposide 
with cholesterol and surfactant showed all characteristic peaks in combination with no 
significant changes as shown in Fig.9.18 and 9.19. Therefore, it could indicate that 
there was no incompatibility between drug and excipients. 
 
9.2.5.2. By Differential scanning calorimetry (DSC) analysis: 
 
The compatibility and interactions between drug, cholesterol and surfactant 
were checked using DSC; results obtained were shown in Fig. 9.20 and 9.21. 
 
 
     
Fig. 9.20: DSC thermogram of Etoposide 
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                 Fig. 9.21: DSC thermogram of Etoposide+ Cholesterol+Surfactant 
Table 9.10: DSC thermogram parameters 
 
 
 
 
 
 
 
 
According to Table 9.10, DSC thermogram showed that there was no major 
difference in onset temperature and peak temperature when compared with pure 
drug’s thermogram. No interaction was found between drug and excipients. The DSC 
studies suggest that the formulation components polysorbate 80 and cholesterol and 
S. 
No. 
            DSC                
      thermogram 
Onset 
temperature 
(°C) 
Peak 
temperature 
(°C) 
1 Drug 262.6 266.9 
2 Formulation EN5 257.6 262.7 
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the drug Etoposide do not interact to form any additional chemical entity but remain 
as a mixture. Therefore, it could indicate that there was no incompatibility between 
drug and excipients. 
9.2.6. In-vitro drug release studies: 
Table 9.11: In-vitro drug release profile of formulation EN1, EN2, EN3. 
S.No. Time 
in 
hours 
Medium EN1 
(%) 
EN2 
(%) 
EN3 
(%) 
1 1  
pH 7.4 
 
P 
H 
O 
S 
P 
H 
A 
T 
E 
 
B 
U 
F 
F 
E 
R 
 
SALINE 
06.19 ± 
0.48 
03.95 ± 
0.65 
01.97 ± 
0.33 
2 2 14.96 ± 
0.65 
09.90 ± 
0.79 
03.64 ± 
0.39 
3 3 18.93 ± 
0.94 
14.75 ± 
0.55 
07.66 ± 
0.31 
4 4 22.74 ± 
1.02 
19.66 ± 
0.96 
12.87 ± 
0.65 
5 5 25.66 ± 
0.63 
23.47 ± 
0.47 
16.79 ± 
0.39 
6 6 28.48 ± 
1.10 
25.81 ± 
1.03 
22.94 ± 
0.39 
7 7 32.34 ± 
0.71 
30.88 ± 
0.71 
25.81 ± 
1.41 
8 8 35.68 ± 
1.10 
33.75 ± 
0.79 
28.48 ± 
0.87 
9 9 39.38 ± 
1.20 
36.82 ± 
1.20 
34.95 ± 
0.80 
10 10 45.59 ± 
0.39 
44.96 ± 
0.55 
37.97 ± 
0.79 
11 24 95.84 ± 
0.86 
89.74 ± 
0.63 
87.91 ± 
0.89 
                            
                              All the values are expressed as mean± S.D., n=3. 
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Table 9.12: In-vitro drug release profile of formulation EN4, EN5, EN6. 
 
S.No. Time 
in 
hours 
Medium EN4 
(%) 
EN5 
(%) 
EN6 
(%) 
1 1  
      pH 7.4 
 
P 
H 
O 
S 
P 
H 
A 
T 
E 
 
B 
U 
F 
F 
E 
R 
 
SALINE 
07.19 ± 
0.87 
05.88 ± 
0.48 
04.58 ± 
0.24 
2 2 09.43 ± 
0.48 
07.97 ± 
0.31 
05.20 ± 
0.55 
3 3 12.87 ± 
0.79 
11.62 ± 
0.39 
07.97 ± 
0.56 
4 4 16.53 ± 
0.79 
15.74 ± 
0.48 
14.75 ± 
0.86 
5 5 25.87 ± 
0.79 
20.75 ± 
0.33 
17.67 ± 
1.03 
6 6 28.79 ± 
0.87 
25.19 ± 
0.41 
23.52 ± 
0.96 
7 7 31.14 ± 
0.31 
29.26 ± 
0.47 
25.45 ± 
0.80 
8 8 37.24 ± 
0.72 
32.75 ± 
0.24 
31.61 ± 
0.78 
9 9 39.85 ± 
0.48 
37.82 ± 
0.65 
35.88 ± 
0.80 
10 10 46.69 ± 
0.80 
43.50 ± 
0.56 
41.78 ± 
0.31 
11 24 94.38 ± 
0.63 
96.62 ± 
0.39 
91.35 ± 
0.86 
  
All the values are expressed as mean± S.D., n=3. 
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Table 9.13: In-vitro drug release profile of formulation EN7, EN8, EN9. 
 
S.No. Time 
in 
hours 
Medium EN7 
(%) 
EN8 
(%) 
EN9 
(%) 
1 1  
pH 7.4 
 
P 
H 
O 
S 
P 
H 
A 
T 
E 
 
B 
U 
F 
F 
E 
R 
 
SALINE 
09.33 ± 
0.71 
05.67 ± 
0.59 
04.16 ± 
0.24 
 
 
2 2 14.96 ± 
0.94 
08.23 ± 
0.39 
05.88 ± 
0.55 
3 3 19.34 ± 
0.71 
11.99 ± 
0.55 
08.65 ± 
0.96 
4 4 25.34 ± 
0.87 
16.53 ± 
0.79 
12.77 ± 
0.48 
5 5 30.30 ± 
1.01 
19.87 ± 
0.63 
17.67 ± 
0.87 
6 6 36.30 ± 
0.78 
24.30 ± 
1.02 
22.84 ± 
0.87 
7 7 41.26 ± 
0.55 
29.21 ± 
0.50 
26.34 ± 
1.02 
8 8 47.94 ± 
1.26 
33.48 ± 
0.31 
31.14 ± 
0.87 
9 9 52.95 ± 
0.86 
37.87 ± 
0.87 
34.74 ± 
1.18 
10 10 55.30 ± 
0.55 
43.97 ± 
0.94 
41.47 ± 
0.31 
11 24 95.37 ± 
0.63 
93.86 ± 
1.75 
94.64 ± 
0.79 
 
All the values are expressed as mean± S.D., n=3. 
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                    Fig. 9.22: In-vitro drug release profile of formulation EN1 
             
                    Fig. 9.23: In-vitro drug release profile of formulation EN2 
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                     Fig. 9.24: In-vitro drug release profile of formulation EN3 
         
         Fig. 9.25: In-vitro drug release profile of formulation EN4 
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                   Fig. 9.26: In-vitro drug release profile of formulation EN5 
      
 Fig. 9.27: In-vitro drug release profile of formulation EN6 
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                     Fig. 9.28: In-vitro drug release profile of formulation EN7 
       
                          Fig. 9.29: In-vitro drug release profile of formulation EN8 
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                      Fig. 9.30: In-vitro drug release profile of formulation EN9 
 
 
                 Fig. 9.31: Comparative in-vitro drug releases of all formulations 
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In-vitro dissolution studies revealed that the release of Etoposide from 
different formulations varies with the characteristics and composition of surfactant 
and cholesterol as shown in Figures 9.22 to 9.31. 
The formulated niosomes showed a most favorable release within 24 hours.  In 
the 24th  hour, the drug release was 95.84%, 89.74%, 87.91%, 94.38, 96.62, 91.35, 
95.37, 93.86 and 94.64% for EN1, EN2, EN3, EN4, EN5, EN6, EN7, EN8 and EN9 
respectively. This was followed by a steady drug release pattern.  
 
From these above data, it showed formulation EN5 released drug mostly at the 
end of 24 hours. The release rate of Etoposide decreased with increasing 
concentration of Cholesterol. But increase in the rate of release was found with 
increasing amount of surfactant. 
 
  Among all the nine formulations, formulation EN5 containing surfactant and 
cholesterol in the molar ratio 1:1 exhibited the highest in vitro drug release of 96.62 at 
24 hours, while the lowest drug release of 87.91 was recorded for formulation 
containing 0.5:1 molar ratio (EN3).  
 
From the above evaluation parameters it was concluded that the   
Formulation EN5 having a maximum percentage of drug release in a controlled 
manner, so the formulation EN5 was selected as the optimized formulation.  
9.2.7. Kinetics of In-vitro drug release:  
                The kinetics of in-vitro drug release was determined by applying the drug 
release data to various kinetic models such as zero order, first order, Higuchi and 
Korsmeyer- Peppas. The result obtained was shown in Table 9.14.  
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Table 9.14: Different kinetic models for Etoposide niosomes (EN1 to EN9) 
 
S.
N
O 
F. 
Code 
Zero 
order 
First 
order Higuchi 
Korsemeyer- 
Peppas Best fit 
model 
R2 R2 R2 R2 n 
1 EN1 0.991 0.839 0.918 0.983 0.801 Zero 
2 EN2 0.990 0.902 0.919 0.989 0.956 Zero 
3 EN3 0.995 0.870 0.875 0.983 1.271 Zero 
4 EN4 0.989 0.862 0.913 0.977 0.870 Zero 
5 EN5 0.998 0.800 0.884 0.985 0.932 Zero 
6 EN6 0.994 0.853 0.876 0.965 1.050 Zero  
7 EN7 0.948 0.924 0.964 0.992 0.769 Peppas 
8 EN8 0.996 0.844 0.891 0.989 0.928 Zero 
9 EN9 0.997 0.810 0.864 0.982 1.058 Zero 
 
           
                          Fig. 9.32: Best fit kinetic release of formulation EN1 
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                           Fig. 9.33: Best fit kinetic release of formulation EN2 
            
                             Fig. 9.34: Best fit kinetic release of formulation EN3 
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                      Fig. 9.35: Best fit kinetic release of formulation EN4 
             
                            Fig. 9.36: Best fit kinetic release of formulation EN5 
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                 Fig. 9.37: Best fit kinetic release of formulation EN6 
         
            
                          Fig. 9.38: Best fit kinetic release of formulation EN7 
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                          Fig. 9.39: Best fit kinetic release of formulation EN8 
             
                         Fig. 9.40: Best fit kinetic release of formulation EN9 
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9.2.8. Test for sterility:  
After in-vitro drug release studies, best formulation was selected. The selected 
formulation was sterilized by membrane filteration. Then sterility testing was 
performed and the results were reported in Table 9.15. 
Growth of micro organisms was noticed during the seven days of incubation 
period in sterilized niosomal formulation and there was no growth. 
 Thus, sterilized niosomal formulation passes the test for sterility and there 
was no growth which indicates niosomes can be administered by parenteral route. 
     Table 9.15: Sterility testing of selected formulation (EN-5) 
S.No. Type  Growth of micro organism 
1 Negative control Presence  
2 Sterilized formulation Absent  
  
9.2.9. In- vivo drug targeting studies:  
 The in- vivo drug targeting was estimated by performing In- vivo tissue 
distribution study for an optimized formulation EN 5. The percentage drug recovered 
in the tissues of various organs for Etoposide niosomes were compared with that of 
free Etoposide. The comparison between the amount of drug targeted from niosomes 
(formulation with highest drug content) and pure drug Etoposide in various organs is 
represented. 
The results obtained were recorded in Table 9.16 and 9.17 and shown in Fig. 
9.41, 9.42 and 9.43 respectively.   
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Table 9.16: In-vivo tissue distribution studies of Etoposide niosomes EN5 
 
S. No 
 
Organs 
 
Percentage drug recovered in 
tissues* (%) 
1.   Liver 41.56 ±0.87 
2. Spleen 25.38 ±0.62 
3. Lung 23.74 ±0.54 
4. Kidney 21.24 ±0.40 
5. Brain 4.76 ±0.76 
                              All the values were expressed as mean S.D., *n=5 
 
            Fig. 9.41: In-vivo tissue distribution studies of Etoposide niosomes EN5 
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            Table 9.17: In- vivo tissue distribution studies of pure Etoposide. 
 
S. No 
 
Organs 
 
Percentage drug recovered in 
tissues* (%) 
1. liver 28.46 ±0.62 
2. Spleen 16.32 ±0.58 
3. Lung 13.63 ±0.73 
4. Kidney 11.89 ±0.71 
5. Brain 3.63 ±0.51 
                              All the values were expressed as mean S.D., *n=5 
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                       Fig. 9.42: In-vivo tissue distribution studies of pure Etoposide 
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                 Fig. 9.43: Comparison of In-vivo tissue distribution studies of  
                                Etoposide niosomes EN5 with pure Etoposide 
The average targeting efficiency of drug loaded niosomes was found to be 
41.56% of the injected as dose in liver, 25.38% in spleen, 23.74% in lungs, 21.24% in 
kidney, 4.76% in brain as compared to the concentration of pure drug was 28.46% in 
liver, 16.32% in spleen, 13.63% in lungs, 11.89% in kidney, 3.63% in brain. The drug 
loaded niosomes showed preferential drug targeting to liver followed by spleen, 
lungs, kidney and brain.  
These results revealed that, the drug loaded niosomes showed preferential 
drug targeting to liver followed by spleen, lungs, kidney and brain. It was also 
revealed that, as compared to pure drug, higher concentration of drug was targeted to 
the organs like liver and lungs after administering the dose in the form of niosomes. 
This may lead to attributed to high macrophage load in these organs and large size of 
liver as compared to spleen and lungs. 
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9.2.10. Stability studies:   
After exposure to refrigerator temperature, room temperature and accelerated 
stability conditions (4ºC ±1ºC , 25ºC± 2ºC at 60% RH±5%RH and 40ºC ±2ºC at 75% 
RH ±5% RH) the formulation was analyzed for various evaluation parameters; results 
are shown in Table 9.18-9.23. 
                   Table 9.18: Stability studies of optimized formulation EN5  
                                                at refrigerator temperature   
Characteristic Initials 1st Month  2nd Month 3th Month  
Drug retained (%)  
92.10 
 
91.85 
 
91.46 
 
91.33 
In vitro drug 
release at 24 hour* 
(%) 
 
96.62±0.39 
 
96.57±0.27 
 
95.79±0.72 
 
94.59±0.79 
Test for sterility      Sterile Sterile Sterile Sterile 
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                     Fig. 9.44: Comparison of drug retained (%) before and after                                                 
            stability studies at refrigerator temperature for optimized formulation EN5 
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        Table 9.19: Percentage in-vitro drug release of selected formulation EN5 after  
                                   stability studies at refrigerator temperature            
                           All the values were expressed as mean S.D., n*=3 
 
          Fig. 9.45: Percentage in-vitro drug release of selected formulation EN5 after  
                               stability studies at refrigerator temperature 
 
S. No 
 
Time  
hours 
Refrigerator temperature 
Initial*  1st month* 2nd month* 3rd month* 
1 1 5.88±0.48 5.933±0.54 6.037±0.48 4.107±0.39 
2 2 7.97±0.31 7.916±0.18 14.86±0.68 5.829±0.39 
3 3 11.62±0.39 11.57±0.56 18.87±1.1 8.594±1.13 
4 4 15.74±0.48 15.69±0.48 22.74±0.79 12.72±0.48 
5 5 20.75±0.33 20.7±0.24 25.61±0.65 17.62±0.71 
6 6 25.19±0.41 25.14±0.5 28.48±1.13 22.79±1.04 
7 7 29.26±0.47 29.21±0.63 32.34±0.96 26.28±0.87 
8 8 32.75±0.24 32.7±0.41 35.52±1.1 31.08±1.02 
9 9 37.82±0.65 37.76±0.72 39.38±1.01 34.68±1.22 
10 10 43.5±0.56 43.45±0.74 45.54±0.41 41.42±0.18 
11 24 96.62±0.39 96.57±0.27 95.79±0.72 94.59±0.79 
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                    Fig. 9.46: Comparison of in vitro drug release before and after 
         stability studies at refrigerator temperature for optimized formulation EN5 
 
      Table 9.20: Stability studies of optimized formulation EN5 at room temperature   
 
Characteristic 
 
Initials 
 
1st Month  
 
2nd Month 
 
3th Month  
Drug retained (%) 92.10 91.13 90.82 90.59 
In vitro drug 
release at 24 hour* 
(%) 
 
96.62±0.39 
 
96.42±0.27 
 
95.63±0.98 
 
94.43±0.55 
Test for sterility Sterile Sterile Sterile Sterile 
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                    Fig. 9.47: Comparison of drug retained (%) before and  
           after stability studies at room temperature for optimized formulation EN5 
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        Table 9.21: Percentage in-vitro drug release of selected formulation EN5 after   
                                         stability studies at room temperature 
                         All the values were expressed as mean S.D., n*=3 
    
Fig. 9.48: Percentage in-vitro drug release of selected formulation EN5 after stability  
                                          studies at room temperature                                                 
 
S. 
No 
 
Time 
hours 
                   
Room temperature 
Initial* 1st month* 2nd month* 3rd month* 
1 1 5.88±0.48 5.776±0.47 5.881±0.18 3.95±0.45 
2 2 7.97±0.31 7.759±0.24 14.7±0.87 5.672±0.65 
3 3 11.62±0.39 11.41±0.83 18.72±0.89 8.438±0.95 
4 4 15.74±0.48 15.53±0.24 22.58±1.02 12.56±0.24 
5 5 20.75±0.33 20.54±0.18 25.45±0.86 17.57±0.94 
6 6 25.19±0.41 24.98±0.24 28.32±1.34 22.63±1.02 
7 7 29.26±0.47 29.05±0.45 32.18±0.71 26.13±0.68 
8 8 32.75±0.24 32.55±0.31 25.36±1.34 30.93±1.07 
9 9 37.82±0.65 37.61±0.45 39.22±0.86 34.53±1.42 
10 10 43.5±0.56 43.29±0.71 45.38±0.16 41.26±0.45 
11 24 96.62±0.39 96.42±0.27 95.63±0.98 94.43±0.55 
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                Fig. 9.49: Comparison of in vitro drug release before and after stability          
                    studies at room temperature for optimized formulation EN5 
 
                Table 9.22: Stability studies of optimized formulation EN5  
                                             at elevated temperature.  
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                     Fig. 9.50: Comparison of drug retained (%) before and after          
            stability studies at elevated temperature for optimized formulation EN5  
 
Characteristic 
 
Initials 
 
1st Month  
 
2nd Month 
 
3th Month  
Drug retained (%) 92.10 91.28 90.18 89.25 
In vitro drug 
release at 24 hour* 
(%) 
 
96.62±0.39 
 
95.68±0.33 
 
94.8±1.01 
 
93.7±0.63 
Sterility testing Sterile Sterile Sterile Sterile 
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      Table 9.23: Percentage in-vitro drug release of selected formulation EN5 after 
                                    stability studies at elevated temperature 
 
S. 
No 
 
Time 
hours 
Elevated temperature 
Initial* 1st month* 2nd month* 3rd month* 
1 1 5.88±0.48 5.046±0.55 5.046±0.24 3.115±0.41 
2 2 7.97±0.31 6.977±0.24 13.92±0.87 4.889±0.65 
3 3 11.62±0.39 10.63±0.83 17.83±0.89 7.759±0.86 
4 4 15.74±0.48 14.75±0.09 21.8±1.02 11.88±0.16 
5 5 20.75±0.33 19.81±0.24 24.67±0.86 16.68±0.94 
6 6 25.19±0.41 24.25±0.16 27.48±1.33 21.85±1.02 
7 7 29.26±0.47 28.27±0.45 31.5±1.04 25.34±0.68 
8 8 32.75±0.24 31.36±0.31 34.63±1.33 30.2±0.98 
9 9 37.82±0.65 36.88±0.5 38.39±0.77 33.75±1.42 
10 10 43.5±0.56 42.51±0.71 44.6±0.16 40.48±0.33 
11 24 96.62±0.39 95.68±0.33 94.8±1.01 93.7±0.63 
                            All the values were expressed as mean S.D., n*=3 
   
      Fig. 9.51: Percentage in-vitro drug release of selected formulation EN5 after   
                                      stability studies at elevated temperature 
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                     Fig. 9.52: Comparison of in vitro drug release before and after      
              stability studies at elevated temperature for optimized formulation EN5                                                                
The studies reveal that, there were no much significant changes in percentage 
drug retained after storage for three months at 4ºC, 25ºC and 40ºC. It was observed 
that the leakage from the vesicle was least at 4ºC followed by 25ºC and 40ºC. In- vitro 
drug release studies revealed that the formulation stored at 4ºC showed 94.59% 
release, the one stored at 25ºC showed 94.43% release and 40ºC batch showed 93.7% 
release after 24 h. 
These result indicate that the drug release from the formulation stored at 4ºC 
was highest followed by formulation stored at 25ºC and 40ºC. This may be attributed 
to phase transition of surfactants and lipid causing vesicle leakage at higher 
temperature during storage. Hence it was concluded from the obtained data, that the 
optimum storage condition for niosomes found to be 4ºC.                         
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10. SUMMARY AND CONCLUSION 
 
The present study was aimed to develop a novel niosomal drug delivery 
system for the treatment of different types of cancer. Nine batches of niosomes (EN1, 
EN2, EN3, EN4, EN5, EN6, EN7, EN8, and EN10) were prepared by using various 
surfactants cholesterol and drug with 32 factorial design by Reverse phase evaporation 
method.  
Preformulation study was carried out for crude drug. The initial part of work 
was started from the identification of drug. Identification of drug was determined by 
melting point and solubility.  
   The niosomes recovery (%) of the formulated niosomes was in the optimum 
range, which indicates a better niosomal recovery. The entrapment efficiency was 
more than fifty percent with all niosomal preparation. The maximum drug entrapment 
was found only in formulation EN5. Entrapment efficiency was found to be a function 
of equimolar concentration of X1 (polysorbate 80) and X2 (cholesterol).  The drug 
loading efficiency of all niosomes showed acceptable range. 
The shape of niosomes was found to be smooth, spherical and bilayered by 
SEM analysis. Smooth surface reveals complete removal of solvent from the 
formulated niosomes and this was the indication of good quality.  
The particle size data showed that niosomes produced were of nanosize and 
had low polydispersity index which indicates relatively narrow particle size 
distribution for all formulations. 
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Zeta potential of all formulated noisome was found to posses the optimum 
surface free energy, which indicates moderate stability with no agglomeration. 
The compatibility studies by FTIR and DSC analysis of niosomes suggest that 
the formulation components polysorbate 80 and cholesterol and the drug Etoposide do 
not interact to form any additional chemical entity but remain as a mixture. Therefore, 
it could indicate that there was no incompatibility between drug and excipients. The 
similarity in peaks indicates there is no incompatibility between drug and the 
surfactants used for formulation. 
From in-vitro release studies it was concluded that formulation EN5 
containing surfactant and cholesterol in equimolar ratio of 1:1 found to be best 
formulation among other formulations, which showing the most desired drug release 
This was followed by a steady drug release pattern, which approximated zero order 
release. It will be considered as optimized formulation. 
 
The optimized formulation EN5 was subjected to sterilization, sterility test and 
in-vivo drug targeting studies and stability studies. The formulation was found to be 
sterile. 
The in-vivo tissue distribution results revealed that, the drug loaded niosomes 
showed preferential drug targeting to liver followed by spleen, lungs, kidney and 
brain. It was also revealed that, as compared to pure drug, higher concentration of 
drug was targeted to the organs like liver and lungs after administering the dose in the 
form of niosomes. 
 
The stability studies revealed that the leakage from the vesicle was least at 4ºC 
followed by 25ºC and 40ºC. The studies reveal that, there were no much significant 
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changes in percentage drug retained after storage for three months at 4ºC, 25ºC and 
40ºC. The drug release from the formulation stored at 4ºC was highest followed by 
formulation stored at 25º C and 40ºC. Hence it was concluded from the obtained data, 
that the optimum storage condition for niosomes found to be 4ºC. 
Out of the nine formulations, it appears that Formulation EN5 has the 
maximum potential in providing niosomal drug delivery system. This formulation was 
considered as best formulation for targeting different type of cancer in order to the 
information obtained from in-vitro and in-vivo studies. 
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11. FUTURE PROSPECTS 
 
In the present work the Novel niosomal delivery system of Etoposide were 
prepared by using polysorbate 80 and cholesterol with 32 factorial design by Reverse 
phase evaporation method. In this investigation, the important parameters like physico 
chemical characterization, in-vitro evaluation, sterility studies and in vivo tissue 
distribution studies of novel niosomal delivery system of Etoposide were done. 
Further detailed investigation and elaborate in-vivo targeting studies using human 
volunteers need to be carried out to establish efficacy of this formulation.  
In order to have a comparative evaluation of in-vivo performance such as 
pharmacokinetic analysis will be performed on plasma concentration time profiles of 
this formulation after i.v. route of administration, since plasma profile is an important 
aspect in understanding biological action of a drug. In-vitro in-vivo correlation studies 
to be performed in future.  
  
 
 
 
 
 
 
Bibliography 
 
 
 
 
 
 
  
 
 
 
 Novel Niosomal Delivery System Of Etoposide                                          Bibliography 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 147 
12.BIBLIOGRAPHY 
 
1. Abdul Hasan Sathali A. and Rajalakshmi G. Evaluation of Transdermal 
Targeted Niosomal Drug Delivery of Terbinafine Hydrochloride, International 
Journal of Pharmaceutical Technology and Research, 2010, 2(3), 2081-2089. 
2. Ajay B. Solanki, Jolly R. Parikh, Rajesh H. Parikh and Mrunali R. Patel. 
Evaluation of Different Compositions of Niosomes to Optimize Aceclofenac 
Transdermal Delivery, Asian Journal of Pharmaceutical Sciences, 2010, 5(3), 
87-95. 
3. Anand Kumar Y., Srinivas S., Hemanth A. and Anitha M. Preparation and 
Evaluation of Niosomes Containing Aceclofenac, Digest Journal of 
Nanomaterials and Biostructures, 2010, 5(1), 249-254. 
4. Anonymous, http://www.en.wikipedia.org/wiki/Etoposide. 
5. Anonymous, http:// www.google.com, drug bank 
6. Anonymous, http://www.pharmainfo.net 
7. Anonymous, http://www.rxlist. Etoposide. 
8. Anonymous, http://www.cancer.org. 
9. Anonymous. Indian Pharmacopoeia. 5 th edn., Government of India, Ministry 
of Health and Family Welfare, The Indian Pharmacopoeial commission, 
Ghaziabad, 2007, 496-500. 
10. Anonymous, The United States Pharmacopoeia XXXII, NF XXVII. The 
United States Pharmacopoeial convention, Rockville, MD, USA. Volume I, 
2009, 1101, 1192. 
 Novel Niosomal Delivery System Of Etoposide                                          Bibliography 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 148 
11. Anupriya kapoor, R.Gahoi and D.Kumar. In-Vitro Drug Release Profile of 
Acyclovir from Niosomes formed with Different Sorbitan Esters, Asian 
Journal of Pharmacy and Life Science, 2011, 1(1), 64-70. 
12. Azmin M.N., Florence A. T., Stuart J.F.B., Vanlerberghes G. and Whittaker J. 
S. The Effect of Niosomes and Polysorbate 80 on the Metabolism and 
Excretion of Methotrexate in the Mouse, Journal of Microencapsulation, 
1986, 3(2), 95-100. 
13. Balasubramanian A, Dasaratha D.M and Vangala A.K. Formulation and in-
vitro evaluation of niosomal encapsulated Daunorubicin hydrochloride, Indian 
Drugs, 2002, 39(1), 27-31. 
14. Banker S.G. and Rhodes C.T. Modern Pharmaceutics, 4th edn., Marcel Dekker, 
Inc, New York, 2008, 529-576. 
15. Brahmankar D.M. and Jaiswal S.B. Biopharmaceutis and Pharmacokinetics: A 
treatise. 2nd edn., Vallabh Prakashan, New Delhi, 2006, 64-65, 335-357. 
16. Chawda Himmat Singh, Jain C. P. and Bairwa Narendra Kumar. Formulation, 
Characterization, Stability and In vitro Evaluation of Nimesulide Niosomes, 
Pharmacophore, 2011, 2 (3), 168-185. 
17.  David G. Rhodes and Almira I. Blazek-Welsh. SEM Imaging Predicts Quality 
of Niosomes from Maltodextrin-Based Proniosomes, Pharmaceutical 
Research, 2001, 18(5), 656-661. 
18. Doijad R.C, Mani F.V, Swati S and Rony M. J. Niosomal drug delivery of 
cisplatin- Development and characterization, Indian Drugs, 2008, 45(9), 713-
718. 
 Novel Niosomal Delivery System Of Etoposide                                          Bibliography 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 149 
19. Dubey subodh, Jain Amit, Mehtha S.C., Gupta Pavan, Jain sandeep and Sahu 
Jagdish. Niosome: An Ultimate Drug Carrier, Drug Invention Today, 2010, 
2(1), 72-77. 
20. Farhan J. Ahmad, Purnima Negi, Dabeer Ahmad, Gaurav K. Jain and 
Gyanendra Singh. Development of a Novel Formulation for Transdermal 
Delivery of an Antidepressant Drug, International Journal of Pharmaceutical 
Sciences and Research, 2011, 2(7), 1766-1771. 
21. Gayathri Devi S. Vekatesh and N. Udupa. Niosomal Sumatriptan succinate for 
nasal administration, Indian Journal of Pharmaceutical Sciences, 2000, 479-
481.  
22. Ghada Abdelbary, and Nashwa El-gendy. Niosome-Encapsulated Gentamicin 
for Ophthalmic Controlled Delivery, AAPS Pharmaceutical Science and 
Technology, 2008, 9(3), 740-747. 
23. Goodman and Gillman’s. The Pharmacological Basis of Therapeutics Mc 
Graw-Hill Medical Publishing Division, New York, 2008, 853-908.  
24. Gupta Manish and Sharma Vimukutha. Targeted Drug Delivery System: A 
Review, Research journal of chemical sciences, 2011, 1(2), 135-138. 
25.  Gyanendra Singh, Hemant K Raghuvanshi, Anubhav Anand, Rakesh Pundir 
and Harinath Dwivedi. Targeted Delivery of Rifampicin by niosomal drug 
delivery system, Journal of Pharmacy Research, 2010, 3(5), 1152-1154. 
26. Heinz Lullman, Klaus Mohr, Albert Ziegler and Detlef Bieger. Color Atlas Of 
Pharmacology, 2nd edn., Georg Thieme Verlag, New York, 2000, 296-299. 
 Novel Niosomal Delivery System Of Etoposide                                          Bibliography 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 150 
27.  Ismail Mouzam, Dehghan M.H.G. and Shaikh Samina M. Development and 
Characterization of Salmeterol Xinafoate Niosomes for Nasal Delivery, Indian 
Journal of Pharmaceutical Education and Research, 2011, 45(2), 121-127. 
28. Jaydeep D Yadav, Priyanka R., Kulkarni A Vaidya and Gurubas T Shelke. 
Niosomes: A Review, Journal of Pharmacy Research, 2011, 4(3), 632-636. 
29.  Jigar Vyas, Puja Vyas, Dhaval Raval, and Paresh Paghdar. Development of 
Topical Niosomal Gel of Benzoyl Peroxide, International Scholarly Research 
Network, 2011, 1-6. 
30. Kandasamy Ruckmani and Veintramuthu Sankar. Formulation and 
optimization of Zidovudine niosomes, AAPS Pharmaceutical Science and 
Technology, 2010, 11(3), 1119-1127. 
31. Khar R.K. and Vyas S.P. Controlled drug delivery concepts and advances, 
Vallabh Prakashn Publishers, Delhi, 2008, 511-534. 
32.  Kenneth Hande, Mark Messenger, Judy Wagner, Mary Krozely and Sanjeev 
Kaul. Inter- and Intrapatient Variability in Etoposide Kinetics with Oral and 
Intravenous Drug Administration, Clinical Cancer Research, 1999, 5, 2742–
2747. 
33.  Kumar Abhinav, Pal jogender lal, Jaiswal Amit and Sing Vishwabhan. 
Review on niosomes as novel drug delivery system, International research 
journal of pharmacy, 2011, 2(5), 61-65. 
34. Lakshmi P.K. and Shyamala Bhaskaran. Comparative Evaluation of Niosome 
Formulations Prepared by Different Techniques, Acta Pharmaceutica 
Sciencia, 2009, 51, 27-32. 
 Novel Niosomal Delivery System Of Etoposide                                          Bibliography 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 151 
35. Lakshmi P.K. and Shyamala Bhaskaran. Phase II Study of Topical Niosomal 
Urea Gel - An Adjuvant in the Treatment of Psoriasis, International Journal of 
Pharmaceutical Sciences Review and Research, 2011, 7(1), 1-7. 
36.  Magharla Dasaratha Dhanaraju, Nandhakumar Sathyamoorthy,Vankayalu 
Devendiran Sundar, Suresh C. Preparation of poly (epsilon-caprolactone) 
microspheres containing etoposide by solvent evaporation method, Asian 
Journal of Pharmaceutical Sciences, 2010, 5 (3), 114-122. 
37.  Manavalan R. and Ramasamy S. Physical Pharmaceutics, Vignesh Publisher, 
Chennai, 2004, 288-299. 
38. Manivannan Rangasamy, Balasubramaniam Ayyasamy and Senthilkumar 
Raju. Formulation and in vitro Evaluation of Niosome Encapsulated 
Acyclovir, Journal of Pharmacy Research, 2008, 1(2), 163-166. 
39.  Meenakshi Bharkatiya, Rajesh Kumar Nema and Maheep Bhatnagara. 
Formulation and Evaluation of Metoprolol Tartrate Entrapped Niosomes, 
International Journal of Chemical Sciences, 2010, 8(4), 2055-2062. 
40.  Pandey Shivanand. Development and Characterization of Cefpodoxime 
Proxetil Niosomes, International Journal of Pharma World Research, 2010, 
1(3), 1-11. 
41.  Pavala Rani N., Suriyaprakash T.N.K. and Senthamarai R. Formulation and 
Evaluation of Rifampicin and Gatifloxacin Niosomes on Logarithmic-Phase 
Cultures of Mycobacterium Tuberculosis, International Journal of Pharma 
and Bio Sciences, 2010, 1(4), 379-387. 
42.  Popli H and Mini S.Nair. Niosomal delivery of Tenoxicam, Indian Journal of 
Pharmaceutical Sciences, 1996, 163-166. 
 Novel Niosomal Delivery System Of Etoposide                                          Bibliography 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 152 
43. Pratap S. Jadon, Virendra Gajbhiye, Rajesh S. Jadon, Kavita R. Gajbhiye and 
Narayanan Ganesh. Enhanced Oral Bioavailability of Griseofulvin via 
Niosomes, AAPS Pharmaceutical Science and Technology, 2009, 10(4), 1186-
1192. 
44.  Rajesh Z. Mujoriya, Ramesh Babu Bodla, Kishore Dhamanle, Devendra 
Singh and Logesh Patle. Niosomal Drug Delivery System: A Magic Bullet, 
Journal of Applied Pharmaceutical Science, 2011, 1(9), 20-23. 
45. Raju Jukanthi, Deepthi Annakula, Madhukar Rao Errabelli, Suresh Bandari 
and Prabakar Reddy Verareddy. Provesicular Drug Delivery System: An 
Overview and Appraisal, Scholars Research Library, 2010, 2(4), 135-146. 
46. Ravi Kumar, Shivji Kumar, Shyam Shankar Jha and Amit Kumar Jha. 
Vesicular System – Carrrier For Drug Delivery, Pelegia Research Library, 
2011, 2(4), 192-202. 
47. Raymond C Rowe, Paul J Sheskey and Paul J Weller. Hand book of 
pharmaceutical excipients, Pharmaceutical press, London, 2006, 182-184, 
580-584.  
48. Robinson J.R. and Lee V.H.L. Controlled drug delivery fundamentals and 
applications, 2nd edn., Informa Health care, Inc., New York, 2009, 462-463. 
49. Roopa Karki, Mamatha G.C., Subramanya G. and Udupa N. Preparation, 
Characterization and Tissue Disposition of Niosomes Containing Isoniazid, 
Rasayan Journal of Chemistry, 2008, 1(2), 224-227. 
50. Sambhakar S., Singh B., Paliwal S.K. and Mishra P.R. Niosomes as a 
Potential Carrier for Controlled Release of Cefuroxime Axetil, Asian Journal 
of Biochemical and Pharmaceutical Research, 2011, 1(1), 126-136. 
 Novel Niosomal Delivery System Of Etoposide                                          Bibliography 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 153 
51.  Sanaa A. El-Gizawy, Ismail A. Attia, Medhat A. Fouda and Ahmed M. 
Donia. Influence of a Niosomal Formulation on the Oral Bioavailability of 
Acyclovir in Rabbits, AAPS Pharmaceutical Science and Technology, 2007, 
8(4), 1-7. 
52. Sandeep Kumar Sharma, Meenakshi Chauhan and Narayanapillay Anilkumar. 
Span-60 Niosomal Oral Suspension of Fluconazole: Formulation and In-Vitro 
Evaluation, Journal of Pharmaceutical Research and Health Care, 2009, 1(2), 
142-156. 
53. Shobha Rani R.H. Text book of Industrial Pharmacy drug delivery systems, 
and cosmetics and Herbal drug technology, Orient Longman Private Ltd, 
Chennai, 2008, 1-3, 98-125. 
54. Skoog D.A, Holler F. and Nieman S. Principles of instrumental analysis. 5th 
edn., Thomson Asia Pvt. Limited, Singapore, 1996, 410-413. 
55. Stanley R. Hamilton and Laure A. Aaltonen. Pathology and Genetics of 
Tumours of the Digestive System, IARC Press, Lyon France, 2000, 9, 20, 57, 
69,157. 
56. Surender Verma, S.K. Singh, Navneet Syan, Pooja Mathur and Vinay 
Valecha. Nanoparticle vesicular system: A versatile tool for drug delivery, 
Journal of Chemical and Pharmaceutical Research, 2010, 2(2), 496-509. 
57. Sweetman S.C., Martindale The Complete drug reference, 36th edn., The 
Pharmaceutical press, London, 2009, 718. 
58. Varaporn Buraphacheep Junyaprasert, Veerawat Teeranachaideekul and 
Tasaneeya Supaperm. Effect of Charged and Non-ionic Membrane Additives 
 Novel Niosomal Delivery System Of Etoposide                                          Bibliography 
Adhiparasakthi College of Pharmacy, Melmaruvathur. Page 154 
on Physicochemical Properties and Stability of Niosomes, AAPS 
Pharmaceutical Science and Technology, 2008, 9(3), 851-859. 
59.  Vedha Hari B.N. and Samyuktha Rani B. Niosomal Formulation of Orlistat: 
Formulation and In-Vitro Evaluation, International Journal of Drug 
Development & Research, 2011, 3(3), 300-311.  
60. Vyas Jigar, Vyas Puja, and Sawant Krutika. Formulation and Evaluation of 
Topical Niosomal Gel of Erythromycin, International Journal of Pharmacy 
and Pharmaceutical Sciences, 2011, 3(1), 123-126. 
61. Vyas SP, Khar R.k. Targeted and Controlled drug delivery, Novel carrier 
systems, 1st edn, CBS publishers, New Delhi, 2002, 39, 249, 331. 
62. Yan-Zhuo Zhang, Jin-Ming Li, Jun-Gang Ren, and Yun-Zhi Qu. Preparation 
of Stealthy Etoposide Proliposomes and the Pharmacokinetics in Rabbits, 
Journal of Chinese Pharmaceutical Sciences, 2008, 17, 303–308. 
 
 
